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ABSTRACT 
Identifying Biomarkers for Resistance to Novel Cisplatin Analogues in Human 
Lung, Breast and Prostate Cancers 
by 
Becky Michelle Hess 
Dr. Bryan L. Spangelo, Examination Committee Chair 
Professor of Chemistry 
University of Nevada, Las Vegas 
Cisplatin is a common therapeutic agent used in cancer treatment. Unfortunately, 
resistance to cisplatin in addition to severe side effects limits its use in cancer treatment. 
Two novel cisplatin analogues, 4DB and 4TB were shown to have varying cytotoxicity in 
lung, breast and prostate cancer cells. The hypothesis for this study states that the 
differences in 4DB and 4TB cytotoxicity among different tissue types is due to the type 
and efficiency of DNA repair mechanisms involved in response to these drugs. 
To test the hypothesis, proteins involved in the rate limiting step of nucleotide 
excision repair (NER) and mismatch repair (MMR) mechanisms were disrupted using 
stable shRNA transfectants. Survival assays using these cell lines revealed that 
suppression of MMR enhanced survival in breast and lung cancer cells with respect to 
cisplatin treatment. Suppression of NER enhanced sensitivity of prostate cancer cells to 
4TB. 
i i i 
Microarray analysis of 4DB treated cells showed repeated over expression of the 
CHOP gene, indicating DNA damage signalling. Repeated over expression of ZNT1 and 
MT-1L genes were identified in lung and prostate cells in response to cisplatin and 4TB 
treatment, indicating their capacity to mitigate drug cytotoxicity in these tissue types. 
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CHAPTER 1 
INTRODUCTION 
1.1 Purpose of the Study 
Cancer is currently the second leading cause of death in the United States. The 
American Cancer Society reported that approximately 1.5 million new cases of cancer 
were diagnosed in 2008 and half of those diagnosed are expected to die from the 
disease. Of these new cases, approximately 185,000 will be diagnosed with breast 
cancer, 215,000 will be diagnosed with lung cancer and 186,000 will be diagnosed 
with prostate cancer. Treatments for these cancers include surgical resection of the 
tumor, chemotherapy, radiation and, in the cases of breast and prostate cancer, 
hormone therapy (American Cancer Society, 2008 ). 
Multiple chemotherapeutic drugs are currently available and these drugs are 
known to have inconsistent efficacy among different patients (Anguiano et al, 2008). 
Additionally, these drugs induce various side effects including fatigue, hair loss and 
nausea. A specific chemotherapeutic drug, cisplatin, has been used in the successful 
treatment of testicular, ovarian, bladder and neck cancers. Unfortunately, severe side 
effects with this drug have been reported including renal toxicity, hearing loss and 
nerve damage. In addition to these severe side effects, cisplatin is ineffective in the 
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treatment of many malignant tumours including lung carcinomas, colon and rectal 
adenocarcinomas (Elwell 2006). For these reasons, the development of more effective 
chemotherapeutic drugs with fewer side effects is needed. A complete understanding 
of drug function on the cellular level will support the development of customizing 
drug treatment to individual patients based on protein expression profile, thus 
avoiding the current trial-and-error method of prescribing chemotherapeutic drugs. 
1.2 Significance of the Study 
The characterization of drug uptake, DNA repair response and overall survival of 
different cancer types to two novel cisplatin analogues, 4,4'-ditertbutyl 2,2'-
bipyridine dichloroplatinum (4TB) and 4,4'-dibutyl 2,2'- bipyridine dichloroplatinum 
(4DB), can provide detailed protein expression profiles that are ultimately related to 
successful chemotherapeutic treatment. The data derived from these experiments can 
have the potential to determine the protein biomarkers that lead to either poor or 
successful outcomes with each drug type. Understanding the protein expression 
profiles would allow screening of individual patient protein biomarkers to determine a 
patient's sensitivity or resistance to a chemotherapeutic drug. Ultimately, physicians 
will individualize patient treatment by selecting the drug that is most likely to 
successfully treat the patient's cancer. 
2 
1.3 Research Questions 
In order to determine potential biomarkers and other factors responsible for 
variations in lethality observed upon treatment with cisplatin and cisplatin analogues 
in different cancer tissue types, the following study will generate data related to the 
following tasks: 
1) Characterize drug uptake and drug clearance over time in whole cells in wild 
type breast, prostate and lung cancer cell lines; 
2) Determine the levels of platinum-DN A adducts formed over time with each 
drug in all wild type cell lines; 
3) Determine by microarray analysis which genes are expressed in the wild type 
cell lines in response to drug treatment; 
4) Suppress DNA repair mechanisms, nucleotide excision repair and mismatch 
repair, using short hairpin RNA, to determine the effects on drug efficacy. 
3 
CHAPTER 2 
REVIEW OF RELATED LITERATURE 
2.1 Cisplatin 
Cisplatin (cw-diaminodichloroplatinum, CDDP), illustrated in Figure 1, is 
a compound with a platinum center bound to two ammonia and two chlorine groups 
in a cis conformation. Cisplatin was first approved for use as an anticancer drug in 
1979, and it is still being used today in the treatment of cancer (Elwell et al., 2006). 
Although shown to be effective against testicular, ovarian and bladder cancers, the 
drug has limited efficacy in lung and colon cancers (Stewart, 2007).The drug also has 
severe, dose-limiting, side effects including neuropathies, renal toxicity and 
ototoxicity (Elwell et al., 2006). An additional drawback to the use of cisplatin is the 
propensity of patients to develop resistance to the drug, which requires physicians to 
prescribe alternate chemotherapeutics in a "trial and error" approach (Anguiano et al., 
2008). 
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Figure 1: Structure of the chemotherapeutic drug, cisplatin http://upload.wikimedia.org/. 
The cytotoxic effects of cisplatin are the result of the covalent adduct formation 
between the platinum center of the drug and either DNA or proteins (Eastman, 1987). 
When the drug enters solution, the chlorides are easily displaced by water molecules, 
resulting in a [Pt(NH3)2(OH2)2]2+ or Pt(NH3)2(OH)2 intermediate compounds. However, 
these newly formed hydroxyl and water ligands are labile and can be easily displaced, 
thus allowing the formation of covalent adducts between the platinum molecule and a 
cellular target (Chaney et al., 2005). The primary cause of cisplatin cytotoxicity is 
hypothesized to be the formation of DNA intrastrand or interstrand cross links as follows: 
intrastrand (GpG), intrastrand (ApG), intrastrand (GpNpG) or interstrand (G-G). Of the 
aforementioned cross linkages formed, intrastrand GpG adducts predominate (Figure 2). 
Elucidation of the structure of cisplatin bound to DNA reveals that adduct 
formation results in a 60 to 80° bend in the DNA which is in the direction of the major 
groove, resulting in minor groove widening (Chaney et al., 2005). Although these adducts 
are believed to be responsible for the lethality of cisplatin, only 1% of the administered 
drug results in DNA adduct formation. One of the reasons for the low percentage of drug 
binding the DNA is because cisplatin can also bind intracellular proteins. Formation of 
adducts with intracellular proteins in the cytosol limits the amount of drug that ultimately 
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gains access to DNA. Once in the nucleus, cisplatin can also bind nuclear proteins, 
including histones, which has been shown to prevent the remodeling of chromatin, 
thereby preventing transcription (Mymryk et al., 1995). The insult to these genomic 
structures and other intracellular proteins results in programmed cell death, or apoptosis 
(Wang et al, 2005). 
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f V "NH2 I 
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Figure 2: Mechanism of formation of an intrastrand GpG adduct. 
2.2 Second Generation Analogues 
Acquired drug resistance coupled with the severe side effects of cisplatin sparked 
interest in the development of second generation cisplatin analogues. Several of these 
new drugs are currently prescribed as chemotherapeutics. These drugs were all designed 
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with a central platinum atom and include carboplatin, oxaliplatin and nedaplatin (Wang et 
al., 2005). Each of the analogues is thought to function in the same manner as cisplatin, 
with the central platinum forming adducts with intracellular proteins and with DNA. 
These drugs induce less severe and more tolerable side effects; unfortunately, all three of 
these analogues have been shown to be less effective than cisplatin in the treatment of 
cancer (Marcel Gielen et al., 2005). Due to the limited success of oxaliplatin (Figure 
3A), carboplatin (Figure 3B) and nedaplatin (Figure 3C), the need for continual 
development of cisplatin analogues with increased efficacy and reduced general toxicity 
was realized (Elwell et al, 2006). 
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Figure 3: Structures of second generation cisplatin analogues, oxaliplatin (A), carboplatin 
(B) and nedaplatin (C) http://upload.wikimedia.org/. 
Synthesis of more complicated chemotherapeutics containing a bipyridine ring 
structure began in 1992 with fluorinated alkyl groups at the 4 and 4' positions (Garelli et 
al., 1992b); however, these drugs were not reported to have increased efficacy over 
cisplatin (Garelli et al., 1992a). More recent studies have shown that the addition of short 
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alkyl groups, as shown in Figure 4, at the 4 and 4' positions induce significantly 
increased apoptosis in lung, breast and prostate cancers (Elwell et al., 2006). 
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Figure 4: Structures of cisplatin analogues containing a bipyridine ring system, 
dichloro(4,4'-dimethyl-2,2'-biyprindine)platinum(A), dichloro(4,4'-diethyl-2,2'-
bipyridine)platinum (B), and dichloro(4,4'-dipropyl-2,2'-biyprindine)platinum. 
The initial success of these analogues lead to the production of dichloro(4,4'-
ditertbutyl-2,2'-bipyridine)platinuni (4TB) and dichloro(4,4'-dibutyl-2,2'-
bipyridine)platinum (4DB) (Figure 5) within the current laboratory group to determine 
the effects of bulkier or lengthier alkyl groups extending from the bipyridine ring system. 
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Figure 5: Structures of cisplatin analogues containing abipyridine ring system, 
dichloro(4,4'-dibutyl-2,2'-biyprindine)platinum (4DB) and dichloro(4,4'-tertbutyl-2,2'-
bipyridine)platinum (4TB). 
Clonogenic survival assays with these compounds in lung, prostate and breast 
cancer cell lines conducted by Vo et al. revealed that the 4DB chemotherapeutic drug was 
more efficacious than cisplatin in all cell lines. The 4TB drug had different results among 
the three tissue types. In the lung cancer cell line, the drug was shown to ineffective at all 
concentrations. In the prostate cancer cell line, 4TB was more efficacious than cisplatin, 
but less efficacious than 4DB. In the breast cancer cell line, 4TB was as efficacious as 
4DB which was nearly 125 times more potent than cisplatin. The findings from these 
assays raised important questions regarding the rational design of cisplatin analogues. 
Understanding the different factors in each tissue type that result in the observed 
cytotoxicity to each drug can lead to the rational drug design of new generation 
chemotherapeutics. In addition, these data would support more individualized treatment 
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regimens. Completing gene and protein expression profiles of patient tumours and 
matching them against the developed criteria for each drug would allow a physician to 
prescribe the most efficacious drug in the first round of patient therapy. 
2.3 Gene Expression Profiles 
Using microarray analysis, the genes involved in response to cisplatin have been 
elucidated for many tissue types (Stewart et al., 2006). In addition to cellular responses 
to the drug presence, proteins responsible for drug resistance or sensitivity have also been 
identified (Stewart et al, 2006). For example, in ovarian cancer cells characterized as 
resistant to cisplatin, Claudin 4 (CLDN4) was shown to be over expressed (Stewart et al., 
2006). CLDN4 is a component in the formation of tight junctions between cells and is 
identified as an integral membrane protein; aberration of these junctions has been 
associated with the development of cancer (Gonzalez-Mariscal et al., 2003). In the 
current study, genes of interest include those that are involved in anti-apoptotic pathways, 
drug transport and modulation of cellular stress. 
The use of gene profiling in lung, breast and prostate cancer cell lines with 4DB 
and 4TB in vitro has the potential to reveal the genes responsible for the observed 
cytotoxicity associated with these drugs. Understanding the mechanisms involved in the 
response to the drugs for each tissue type has the potential to improve cancer treatment 
success. 
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2.4 Genes of Interest 
Cisplatin exerts its lethality through the formation of covalent adducts with DNA; 
however, these lesions can be repaired through two DNA repair mechanisms: nucleotide 
excision repair (NER) and mismatch repair (MMR) (Chang et al., 2005; Stojic et al., 
2004). Therefore, proteins involved in these DNA repair mechanisms are of interest. 
Additionally, proteins directly involved in apoptosis are also of interest because over 
expression of either anti-apoptotic, specifically Bcl-2, or pro-apoptotic proteins, 
specifically; Bid, Bad and Bax; have been associated with general chemoresistance 
(Biswas et al., 2004). 
Cisplatin adducts are poorly repaired, regardless of the repair mechanism 
involved, when the lesion is bound by high-mobility-group (HMG) proteins. When an 
HMG protein binds an adduct, its presence prevents recognition of the adduct by proteins 
involved in DNA repair processes (Jordan et al., 2000). HMG proteins bind 
nonspecifically to DNA and induce sharp bends in the DNA structure upon binding. For 
example, as shown in Figure 6, when HMGB1 binds the DNA it inserts a phenyl group 
into the groove created by cisplatin binding. Thus, these proteins preferentially bind to 
DNA that is already distorted which accounts for their propensity to bind to cisplatin-
DNA adducts (Farid et al., 1996). Therefore, elevation of HMG protein levels in treated 
cells compared to untreated samples will be of interest in determining if these proteins 
play a role in cisplatin cytotoxicity. 
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Figure 6: Binding of HMGB1 to DNA in a region containing a cisplatin-DNA adduct 
http://gibs.ws/cisplatin.com. 
The repair of cisplatin-DNA adducts is completed by the NER and MMR 
mechanisms. Each of these repair systems has rate limiting steps which provide genes of 
interest for this study. With respect to NER, the excision repair cross complement 1 
(ERCC1) protein is responsible for the rate limiting step in the repair process, whereas 
the MutS Homo log 2 (MSH2) protein is responsible for the rate limiting step in the MMR 
process (Chang et al., 2005; Stojic et al, 2004). Both the rate and efficiency of each DNA 
repair process is thought to be critical to the successful removal of cisplatin-DNA 
adducts; therefore, the ERCC1 and MSH2 proteins are a focus in the current study. 
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Mismatches in DNA can be identified due to their lack of Watson-Crick base 
pairing, often resulting in modification of the overall DNA structure. MSH2 is 
responsible for recognizing mismatches in the DNA and initiating the MMR process. 
MSH2 forms a heterodimer with MSH6 which results in the formation of a sliding clamp. 
The MSH2/MSH6 complex formation recruits both MLH1 and PMS2 which forms a 
second heterodimer. This complete complex, as illustrated in Figure 7, can traverse DNA 
structures in both the forward and reverse directions to identify the compromised section 
of the strand (Stojic et al., 2004). 
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Figure 7: Mechanism of MMR, activated by the formation of cisplatin-DNA adducts 
(Stojic et al., 2004). 
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NER has been identified as the predominant DNA repair process which responds 
to the presence of cisplatin-DNA adducts. The NER mechanism, like MMR, is initiated 
by [1] damage recognition; [2] unwinding of the DNA strands; [3] exonuclease activities 
on either side of the lesion; and [4] removal of the damaged oligonucleotides and 
resynthesis of the removed section (Chang et al., 2005). As shown in Figure 8, there are 
multiple proteins involved, and although ERCC1 is not responsible for damage 
recognition, its initiation of the incision at the 5' end of the damage site is the rate 
limiting step of the DNA repair mechanism. 
Figure 8: Mechanism of NER, activated by the formation of cisplatin-DNA adducts. 
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2.5 Hypothesis 
Cisplatin has been widely used in the treatment of cancer, but severe dose-
limiting side effects coupled with the propensity of patients to develop resistance to the 
drug warrants the development of more efficacious chemotherapeutics. Characterization 
of gene expression in response to the cisplatin analogues in different cancer types can 
lend insight into the mechanisms involved in cytotoxicity effectiveness. These data can 
be used in the rational drug design of future chemotherapeutic drugs. Further, 
understanding the response to each drug will allow the development of criteria for 
optimum drug usage. For example, if a drug is known to perform well in patients with 
suppressed NER activity, a patient can be screened for these related proteins in order to 
determine if the drug is an appropriate part of overall treatment. 
The hypothesis for the current study is that the differences in observed cytotoxicity 
between 4DB and 4TB among different tissue types is due to the type and efficiency of the 
DNA repair mechanisms involved in response to these drugs. To test the hypothesis, the 
level of drug uptake as well as rate of repair of platinum-DNA adducts for cisplatin, 4DB 
and 4TB will be determined using inductively coupled plasma mass spectrometry (ICP-
MS) in the wild type lung (A-549), breast (MDA-MB-435) and prostate (DU-145) cancer 
cell lines. Microarray analysis will also be conducted on the wild type cell lines following 
exposure to each of the three drugs to assess the genes involved in observed drug 
sensitivity or resistance. The MMR and NER mechanisms will be disrupted using short 
hairpin RNA (shRNA) against MSH2 or ERCC1 in each of the cell lines. Once these 
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transfected cell lines are developed, the cytotoxicity of each of the drugs will be 
determined using cell viability assays. 
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CHAPTER 3 
MATERIALS AND METHODS 
All chemicals and reagents used were of the highest quality grade. All cell lines 
were maintained at 95% humidity, 5% CO2 and 37 °C unless otherwise stated. 
Ultrapure water was used in sample and drug preparations requiring the use of water. 
3.1 Cell Culture 
The human breast cancer cell line, MDA-MB-435, human prostate cancer cell 
line, DU-145, and human lung cancer cell line, A-549, was obtained from the 
American Type Culture Collection (Manassas, VA, USA). MDA-MB-435 and A-549 
cells were both cultured in Minimum Essential Medium, Eagle (MEM) (Earle's Salts 
and L-glutamine, Invitrogen, USA) supplemented with 10% fetal bovine serum 
(Invitrogen, USA), 25mM HEPES pH 7.4 (Sigma-Aldrich, USA) and 1% penicillin-
streptomycin (Invitrogen, USA). Transfected cell lines derived from A-549 or MDA-
MB-435 were also cultured in MEM medium which contained 0.5ug/mL puromycin 
(Sigma-Aldrich, USA). DU-145 cells were culture in RPMI 1640 medium (Earle's 
Salts and L-glutamine, Invitrogen, USA) supplemented with 10% fetal bovine serum 
(Invitrogen, USA), 15mM HEPES pH 7.4 (Sigma-Aldrich, USA) and 1% penicillin-
streptomycin (Invitrogen, USA). Transfected cell lines derived from DU-145 cells 
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were also cultured in RPMI 1640 medium which contained 0.5|ug/mL puromycin. All 
cells were incubated at 37 °C in a 95% humidity environment containing 5% CO2. 
Cell harvests were obtained by washing cells three times in phosphate buffered saline 
(PBS at pH 7.2) which did not contain CaCl2 or MgCl2 (Invitrogen, USA), followed 
by chemically detaching adherent cells by exposing the cells for 10 min to trypsin-
EDTA (0.25% Trypsin with 53mM EDTA) in HBSS without calcium or magnesium 
(Invitrogen, USA). Fresh medium was added following the 10 min trypsin exposure 
to inactivate the trypsin. Cells counts were performed using a Zl Beckman Coulter® 
Particle Counter (Fullerton, CA). 
3.2 Zl Beckman Coulter® Particle Counter 
Cell suspension (0.1 mL) was added to 9.9 mL of an azide-free isotonic diluent 
(Isoton) solution (Val-Tech Diagnostics Inc., Pittsburgh, PA). The solution was 
stirred and placed in the Zl Beckman Coulter® Particle Counter (Fullerton, CA). 
Two or three measurements were averaged and used to calculate the cell density of 
the solution. 
3.3 Preparation of Cisplatin, Dichloro(4,4'-dibutyl-2,2'-biyprindine)platinum, 
Dichloro(4,4'-tertbutyl-2,2'-bipyridine)platinum and Puromycin 
A 50 mM stock of cisplatin was prepared by dissolving 0.150 grams of 300.05 
g/mol cisplatin (CDDP; Sigma-Aldrich, USA) in 10 mL of dimethyl sulfoxide 
(DMSO; Sigma-Aldrich, USA). The solution was sterile filtered using a syringe 
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(Becton Dickinson, USA) with an attached 0.2 um nylon membrane syringe filter 
(PALL, Ann Arbor, MI). Serial dilutions were completed using 500 uL of the 50 raM 
stock diluted in 4.5 mL of sterile filtered DMSO. 
A 5 mM stock of dichloro(4,4'-dibutyl-2,2'-biyprindine)platinum (4DB) or 
dichloro(4,4'-tertbutyl-2,2'-bipyridine)platinum (4TB), both kind gifts from Dr. 
Byron Bennett, were prepared by dissolving 0.0267 grams of 534.49 g/mol 4TB or 
4DB in 10 mL of DMSO. The solutions were sterile filtered as described previously. 
Serial dilutions were completed using 500 uL of the 5 mM stock diluted in 4.5 mL of 
sterile filtered DMSO. 
A 250 (j,g/mL stock of puromycin (Sigma-Aldrich, USA) was prepared by 
diluting 0.125 mL of the 1 mg/mL stock solution in 4.875 mL of water. The solution 
was sterile filtered using a syringe (Becton Dickinson, USA) with an attached 0.2 urn 
polyethersulfone membrane syringe filter (VWR International, USA). Serial dilutions 
were made by using 1.0 mL of the 250 (ag/mL stock diluted in 9.0 mL of sterile 
filtered water. 
3.4 Transient Short Hairpin RNA Transfection 
Lyphilized short hairpin RNA (shRNA) constructs (OriGene, USA) against MutS 
Homo log 2 (MSH2) or excision repair cross complement 1 (ERCC1) were 
reconstituted in 50 \iL of nuclease-free water (Qiagen, USA). Six well tissue culture 
plates (Becton Dickinson, USA) were seeded with 30 x 103 (MDA-MB-435) cells, 40 
x 103 (A-549) cells or 45 x 103 (DU-145) cells and allowed to grow for 24 hr to 
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obtain a 50-60% confluent cell population. After the incubation period, on the day of 
transfection, the transfection complex was prepared by adding 3 uL of TurboFection 
8.0 (OriGene, USA) to an RNase free tube containing 100 uL of serum free medium 
(MEM for A-549 and MDA-MB-435 or RPMI-1640 for DU-145 cells). The solution 
was mixed by gentle pipetting and allowed to incubate at room temperature for 5 min. 
Following incubation, 3 (xg of the reconstituted construct was added to the 
TurboFectin-containing medium and the solution was mixed by gentle pipetting. This 
complete transfection complex was allowed to incubate at room temperature for 25 
min. The transfection complex was added dropwise to the cells and the plate was 
gently rocked to evenly distribute the complex. The cells were incubated for 24 hr 
then harvested as described above and assayed for the protein of interest using 
Western Blot analysis to determine the appropriate construct to use for stable 
transfection. 
3.5 Stable Short Hairpin RNA or Expression Plasmid Transfection 
Six well tissue culture plates (Becton Dickinson, USA) were seeded with 30 x 10 
(MDA-MB-435) cells, 40 x 103 (A-549) cells or 45 x 103 (DU-145) cells and 
allowed to grow for 24 hr to obtain a 50-60% confluent cell population. For all cell 
lines; MDA-MB-435, A-549 and DU-145; stable cell lines transfected with the empty 
expression vector and shRNA construct against green fluorescence protein (GFP) 
were developed. For the MDA-MB-435 cell line, MSH2 construct 25 and ERCC1 
construct 65 were selected for stable transfection. For the A-549 cell line, MSH2 
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construct 27 and ERCC1 construct 67 were selected for stable transfection. For the 
DU-145 cell line, MSH2 construct 27 and ERCC1 construct 65 were selected for 
stable transfection. The complete transfection solution was prepared and addition of 
the complex to the cells was completed as described above. The cells were again 
incubated with the transfection complex for 24 hr. After the incubation period, the 
cells were harvested and passaged into T-12.5 cm2 tissue culture flasks (Becton 
Dickinson, USA) containing complete culture medium and a final puromycin 
concentration of 0.5 |ig/mL. The stable cell lines were developed as shown in Figure 
9 below. 
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Step 1 
Step 2 
Step3 
Step 4 
Step 5 
Step 6 
Review the cells for confluency of adherent cells and cells in 
suspension until the confluency of cells in suspension is 30% or 
higher, approximately 2 to 3 days. 
Remove the medium, wash the cells one time with PBS and add fresh 
medium containing 0.5 ug/mL puromycin. 
Repeat steps 1 and 2 until defined colonies develop and the confluency 
of these adherent cells is 30% or higher. 
Passage the cells from the T-12.5 cm2 tissue culture flask to a T-25 cm2 
tissue culture flask using fresh medium containing 0.5 ug/mL 
puromycin. 
Repeat steps 1 and 2 until defined colonies develop and the confluency 
of the adherent cells is 80% or higher. 
Passage the cells into anew T-25 cm2 tissue culture flask using fresh 
medium containing 0.5 ug/mL puromycin. Maintain the cell line by 
passaging upon reaching confluency with continuous exposure to 0.5 
jig/mL puromycin to ensure continued expression of the shRNA. 
Figure 9: Procedure for the development of stable cell lines expressing shRNA. The 
incubation environment is maintained at 37 °C, 95% relative humidity and 5% CO2. 
3.6 Colony Formation Assay (Clonogenie Survival) 
Parental MDA-MB-435 (100 x 103), transfected MDA-MB-435 (115 x 103), 
parental A-549 (120 x 103), transfected A-549 (135 x 103), parental DU-145 (130 x 
103) or transfected DU-145 (135 x 103) cells were seeded into T-25 cm tissue culture 
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flasks and maintained with a total volume of 5 mL of MEM or RPMI1640 cell 
culture medium. The transfected cell lines were also supplemented with 100 uL of 25 
ug/mL puromycin, resulting in a final concentration of 0.5 ug/mL puromycin. After 
24 hr of incubation, the cells were treated with varying concentrations of cisplatin, 
4DB or 4TB and incubated for 1 hr whereas control samples were treated with the 
drug vehicle, DMSO. Cells were harvested, counted, and dilutions were prepared such 
that 150 cells (parental and transfected MDA-MB-435) or 200 cells (parental and 
transfected A-549 or DU-145) were sub-cultured in triplicate in 60 mm x 15 mm cell 
culture dishes (Coming Inc., USA). Dishes were incubated at 37 °C , 95% humidity 
and 5% CO2 for 10 days, and stained with crystal violet (0.5% weight/volume crystal 
violet in 95% ethanol, Sigma-Aldrich, USA), and colonies (n >50 cells) were 
counted. Percent survival compared to control cells was measured (n = 3). 
3.7 RNA Extractions 
Cells were passed at the same time each day for a total of three passages and 
maintained at 50-60% confluency. The cells were treated for 1 hr with the EC50 
concentration of cisplatin, 4DB or 4TB. Following treatment, samples designated at 0 
hr were washed three times with 5 mL of PBS then harvested immediately as 
described below. Samples designated as 2 hr, 4 hr or 24 hr were washed three times 
with 5 mL of PBS and fresh medium was then added. The 2 hr, 4 hr or 24 hr samples 
were then harvested as described below. Media was removed from the triplicate flasks 
containing MDA-MB-435, A-549 or DU-145 cells and rinsed three times with 5 mL 
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of PBS. Cells were then harvested and transferred to a 15 mL conical vial. Total RNA 
extractions were then performed using the QIAGEN RNeasy MINI Kit (Qiagen, 
USA) purification system according to the manufacturer's instructions. The resulting 
solution was separated into aliquots for the purpose of microarray analysis, 
quantification, and verification of purity. The aliquots were immediately stored at -70 
°C until further use. 
3.8 RNA Quantification and Purity Verification Using the NanoDrop ND-1000 
To ensure the integrity of the RNA, all samples remained on ice and were handled 
using RNase free materials. A 1:10 dilution of sample to Tris buffer was prepared for 
the purpose of verifying sample purity. The NanoDrop (ND-1000 spectrophotometer, 
Thermo Scientific, USA) instrument was set to zero using RNase free water prior to 
measuring the absorbance of the samples. A total of 2 uL of sample was loaded onto 
the sensor to measure the absorbance at 260 and 280 nm. The sensor was thoroughly 
cleaned using RNase free water between sample readings. Each sample was measured 
twice and the average value was used in data analysis. Concentration of RNA was 
calculated by the NanoDrop software. To verify purity, the samples diluted in Tris 
buffer were measured and only samples with an A260/280 reading within 1.8-2.3 
were used for microarray analysis. 
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3.9 Microarray Analysis 
Asymetrix GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, Santa 
Clara, CA, USA) were used for the study which is a single array with over 47,000 
transcript probe sets representing over 38,500 well-substantiated human genes. 
Windber followed the Affymetrix GeneChip® Expression Analysis Technical Manual 
for all GeneChip array procedures. Briefly, 1 ug of total RNA is used for reverse 
transcription to produce single strand cDNA followed by second strand synthesis to 
form double strand cDNA. After cDNA purification, biotin-labeled cRNA target is 
produced by an in vitro transcription (IVT) reaction using the cDNA template. After 
cRNA purification, an aliquot of the labelled cRNA is run on Agilent's Bioanalyzer 
as a quality control step and another aliquot is quantified using the NanoDrop UV/Vis 
spectrophotometer (NanoDrop). Only high quality RNA with a yield of more than 
10 ug is fragmented and hybridized to Affymetrix GeneChip arrays overnight (18 hr) 
in a temperature-controlled hyb-oven. After hybridization, GeneChip arrays are 
loaded onto a Fluidic Station 450 for washing and staining using the standard 
Affymetrix procedure. After the final wash, the GeneChip arrays are scanned using 
the Affymetrix GeneChip scanner 3000 G7. Scanned images were analyzed using 
Affymetrix data analysis software (GDAS) to generate the raw data. 
Data was analyzed using the GDAS software in order to generate relevant targets 
from each array. The CEL files were imported into GeneSpring microarray analysis 
software (Agilent). All arrays were subjected to GCRMA processing followed by 
subsequent processing using log transformation and global normalization to generate 
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normalized data. Probes with a raw signal intensity below 50 were eliminated, 
resulting in approximately 22,000 probe sets between replicate sample groups for 
further analysis. In order to identify differentially expressed genes for each compared 
group, fold changes of two or higher were used. Potential false positives were 
eliminated by identifying normalized signal values that were inconsistent between 
replicate sample groups. The t-test was used to farther reduce false positive probe 
sets. 
3.10 Western Blot Analysis 
Parental MDA-MB-435 (265 x 103) cells, transfected MDA-MB-435 (290 x 103) 
cells, parental A-549 (300 x 103) cells, transfected A-549 (325 x 103) cells, parental 
DU-145 (300 x 103) cells or transfected DU-145 (325 x 103) cells were seeded into T-
75 cm tissue culture flasks and maintained with a total volume of 10 mL of MEM or 
RPMI 1640 cell culture medium. The transfected cell lines were also supplemented 
with 200 uL of 25 (ig/mL puromycin, resulting in a final concentration of 0.5 ug/mL 
puromycin. After 3 d of incubation, the adherent cells were washed three times with 
10 mL of PBS, discarding each wash. Following the washing procedure, 2 mL of 
trypsin-EDTA was added to the flask and cells were harvested as described 
previously. The cells were centrifuged at 4° C for 5 min at 2,000x g and the resulting 
supernatant was discarded. To the remaining cell pellet, 500 uL of M-PER cell lysis 
buffer (Pierce, Rockford, IL, USA) was added in addition to 20 uL/mL protease and 
10 uL/mL EDTA (Pierce). The tube was then gently vortexed for 5 min. The cells 
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were then centrifuged at 14,000 x g for 15 min at 4 °C to pellet cellular debris. The 
resulting supernatant, containing all cellular proteins, was collected and stored at -20 
°C until further analysis. 
Protein concentrations were determined using the bicinchoninic acid (BCA) 
protein assay (Pierce, Rockford, IL) according to the manufacturer's instructions. 
Different masses of bovine serum albumin (BSA; Sigma-Aldrich, USA) protein 
standards (0, 25, 50, 100,150, 200 (ig) were used to generate a standard curve. Lysates 
were diluted by 35% by adding adding 25% sample loading buffer (PAGEgel, San 
Diego, CA) and 10% DDT reducer (PAGEgel). The samples were placed in boiling 
water for 3 min, and then samples with a volume of 35uL or less were loaded into the 
wells of a pre-casted 12% SDS-PAGE Western blot gel in duplicate (PAGEgel). A 
prestained protein ladder, SeeBlue plus (Invitrogen, USA) was used to ensure transfer 
of protein to membranes and served as a molecular weight marker. Electrophoresis 
was conducted in 1 x PAGEgel SDS running buffer (PAGEgel) according to 
manufacturer's instructions. Briefly, electrophoresis was initiated at 80 mA/gel and 
the current was decreased by 10 mA/gel every 15 min until a current of 50 mA/gel is 
reached. The current is then reduced to 35 mA/gel and allowed to run for 20 min, or 
until the dye front reaches the base of the gel, resulting in a total run time of 75 to 90 
min. Following electrophoresis, the protein is transferred from the gel to a 0.2 urn 
nitrocellulose membrane (PAGEgel) using a constant voltage of 20 V for 80 min 
while in Western transfer buffer (Tris-Glycine-SDS Run/Blot Stock Buffer, 
PAGEgel) and 20% v/v methanol (Sigma-Aldrich). Following the transfer, the 
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membranes are placed in blocking solution with TBST [Western wash, femto TBST 
10X (G-Biosciences, St. Louis, MO)], 0.1% Tween-20 (Sigma-Aldrich, USA) and 5% 
nonfat milk (Nestle Carnation) for 1 hr, then rinsed three times using TBST until the 
solution was clear. The membrane was incubated in primary monoclonal IgG mouse 
anti-human antibody overnight at 4 °C. The primary antibodies were diluted to a 
concentration of 1:200 (MSH2), 1:100 (ERCC1), or 1:1000 (control, 0-Actin) (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA). All antibodies were diluted in TBST 
containing 5% BSA. After incubation, the primary antibody was removed and the 
membrane was subjected to a TBST wash while being rocked for 5 min at room 
temperature. The washing step is repeated a total of three times to ensure complete 
removal of unbound primary antibody. The membranes are then incubated in 
secondary monoclonal IgG goat anti-mouse antibody conjugated to a horseradish 
peroxidise (HRP) (1:2000) for 90 min at room temperature (Santa Cruz 
Biotechnology Inc.). After the incubation, the secondary antibody was removed and 
the membrane was washed three times with TBST as described above. Proteins were 
visualized on the Typhoon multipurpose imager using Enhanced chemiluminescence 
ECL-plus® detection reagent (Amersham, Piscataway, NJ). 
3.11 Cell Cycle Analysis 
Parental MDA-MB-435 (175 x 10 ) cells were seeded in a T-75 cm tissue culture 
flask and allowed to grow for three days. To determine cell cycle phase distribution in 
parental MDA-MB-435 cells following treatment with 4DB, cells were treated for 1 
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hr with the EC50 concentration of the drug whereas the control was treated with the 
drug vehicle, DMSO. Following drug exposure, the media was removed and the cells 
were rinsed three times with PBS. Fresh medium was then added and the cells were 
then incubated for 0, 2, 4 or 24 hr. Following the incubation period, cells were 
harvested and a cell pellet was obtained by centrifuging the cell solution at 4° C for 5 
min at 2,000x g. Cells were washed with 5 mL PBS, centrifitged and resuspended in 
100 JLIL of PBS. To fix the cells, 1 mL of cold 95% ethanol was added slowly while 
vortexing the sample gently. Samples were then stored at 4 °C for at least 24h prior to 
being stained. To analyze the cells, propidium iodide staining was conducted. Fixed 
cells were washed with 2.0 mL of PBS and incubated with 0.1 mL Triton X 1% buffer 
and 0.1 mL RNase at 1 mg/mL for 10 min at room temperature. Propidium iodide 
stain (0.2 mL) at a concentration of 100 ug/mL was added and cells were incubated 
for 30 min in the absence of light at room temperature. Samples were analyzed on the 
Becton Dickinson FACSCalibur (Becton Dickinson, USA) and results were evaluated 
using ModFit LT Version 3.0 (Verity Software House, Topsham, ME). 
3.12 Intracellular Antigen Staining 
Parental MDA-MB-435 (265 x 103) cells, transfected MDA-MB-435 (290 x 103) 
cells, parental A-549 (300 x 103) cells, transfected A-549 (325 x 103) cells, parental DU-
145 (300 x 103) cells or transfected DU-145 (325 x 103) cells were seeded into T-75 cm2 
tissue culture flasks and maintained with a total volume of 10 mL of MEM or RPMI 1640 
cell culture medium. The transfected cell lines were also supplemented with 200 uL of 25 
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ug/mL puromycin, resulting in a final concentration of 0.5 ug/uL puromycin. After 3 d of 
incubation, the adherent cells were washed three times with 10 mL of PBS, discarding 
each wash. Following the wash procedure, cells were harvested by exposure to 5mL of 
0.2% EDTA in PBS for 10 min. Then, 5 mL of appropriate medium was added to 
neutralize the EDTA. A cell count was performed on the cell solution after which, the 
cell solution was separated in 1 x 106 cell aliquots. 
The cell solution was centrifiiged at 1000 rpm for 5 min at 4° C and the resulting 
supernatant was discarded. The cell pellet was then resuspended in 1 mL of fixation 
buffer (Santa Cruz Biotechnology Inc.) and incubated for 30 min at room temperature 
while gently being rotated. The cells were then centrifiiged at 3000 rpm for 5 min at room 
temperature and the resulting supernatant was discarded. The pellet was then resuspended 
in 50mL of PBS and the resulting suspension was centrifiiged at room temperature for 5 
min at 2000 rpm. The supernatant was discarded and then 1 mL of cold permeabilization 
buffer (Santa Cruz Biotechnology, Inc.) was added dropwise while vortexing to the cell 
pellet. The sample was then incubated for 5 min at room temperature while being gently 
rotated followed immediately by centrifugation at room temperature for 5 min at 2500 
rpm. The resulting supernatant was then discarded and the cell pellet was gently 
resuspended in 50 mL of PBS. The sample was then centrifuged at room temperature for 
5 min at 2500 rpm and the resulting supernatant was discarded. The cell pellet was 
resuspended in 100 uL of wash buffer (Santa Cruz Biotechnology Inc.). 
To all samples, 1 ug of primary antibody (MSH2 or ERCC1; Santa Cruz 
Biotechnology, Inc.) was added. To account for nonspecific binding, two samples of the 
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parental cell line were used as controls by treatment with the isoform antibody for 
ERCC1, normal mouse IgG2t» or MSH2, normal mouse IgGi. A third control, one that 
only contains secondary antibody to account for background signal, was also used. For 
this third control, the steps involving primary antibody staining (below) were omitted. 
The solutions were then vortexed briefly, covered and incubated on ice for 30 min. Then, 
1.5 mL of Wash Buffer was added to the sample, followed by centrifugation at room 
temperature for 5 min at 4000 rpm and the resulting supernatant was discarded. The cell 
pellet is resuspended in 100 uL of wash buffer and 1 u£ of secondary antibody 
conjugated to phycoerythrin (goat anti-mouse IgG; Santa Cruz Biotechnology, Inc.). The 
samples were then vortexed briefly, covered and incubated on ice for 30 min. Then, 1.5 
mL of wash buffer was added to the sample followed by centrifugation at 4000 rpm for 5 
min. The resulting supernatant was then discarded. The cell pellet was then resuspended 
in 500 uL of 1% paraformaldehyde in wash buffer and stored for a maximum of 24 hr in 
the absence of light prior to acquiring data. 
Samples were analyzed on the Becton Dickinson FACSCalibur (Becton 
Dickinson) and results were evaluated using ModFit LT Version 3.0 (Verity Software 
House). 
3.13 Fluorescent Microscopy 
Parental MDA-MB-435 (40 x 103) cells were seeded on each slide of a 4-well 
chamber slide and allowed to grow for 24 hr in order to achieve a cell density of 65 to 
70% confluency. The medium was then removed and the wells were washed with PBS. 
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Medium containing the EC50 concentration of 4DB was then added to each well and drug 
exposure continued for 1 hr. Following treatment, the medium was removed and the cells 
were rinsed three times with PBS. Fresh medium was then added and the cells were 
incubated for 0, 2, 4 or 24 hr. At the indicated time point, the medium was removed and 
wells were washed with PBS and stained with 0.5 mL of Hoechst stain (2 ng/mL) and 0.5 
mL of propidium iodide (10 |ig/mL) diluted in PBS. The cells were incubated for 15 min 
and the images were acquired. 
A bright field was obtained by visualizing cells with a phase lamp. Apoptotic 
cells were identified using a mercury lamp with an excitation wavelength of 300 -500 
nm and an ultraviolet filter with an emission wavelength of 435-485 run. Cells that have 
taken up the Hoechst stain were identified as apoptotic. Necrotic cells were identified 
using the mercury lamp and a green filter with an emission wavelength of 600-660 nm. 
Cells were positively identified as apoptotic by appearing red due to the presence of the 
propidium iodide stain being taken up by the cell. The images were obtained using a 
Photometries Cool Snap CCD camera attached to a Nikon Eclipse TE2000-U 
microscope (Nikon Inc. Melvile, NY) and analyzed using MetaVue software (Meta 
Series 6.0/6.1, Universal Imaging Corporation). 
To determine the percentage of apoptosis or necrosis, the following equation was 
employed: 
(Number of positive apoptotic/necrotic cellsN inno/ Total number of eels in the bright field / 
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The three areas of the wells imaged were randomly selected and were scanned in each 
of the control and treated wells (n=3). 
3.14 DNA Extractions 
Following drug treatment, at the indicated time point, cells were washed three 
times using PBS. Cells were then harvested and transferred to a 15 mL conical vial. Total 
DNA extractions were then performed using the GenElute Mammalian DNA Miniprep Kit 
(Sigma-Aldrich, USA) according to the manufacturer's instructions. The resulting solution 
was separated into aliquots for the purpose of quantification, verification of purity and 
Inductively Coupled Plasma-Mass Spectroscopy analysis for total platinum concentration. 
Samples were stored in the -70 °C freezer until analysis. 
3.15 DNA Quantification and Purity Verification using the NanoDrop ND1000 
To ensure the integrity of the DNA, all samples remained on ice and were handled 
using nuclease-free materials. The ND-1000 spectrophotometer was set to zero using 
elution buffer (Sigma-Aldrich, USA) prior to measuring the absorbance of the samples. A 
total of 2 uL of sample was loaded onto the sensor to measure the absorbance at both 260 
nm and 280 nm. The sensor was thoroughly cleaned using nuclease-free water between 
sample readings. Each sample was measured twice and the value was in data analysis. To 
verify purity, the A260/280 ratio was calculated by the NanoDrop software and only 
samples with an A260/280 ratio within 1.9-2.4 were used for further analysis. 
33 
3.16 Determining Platinum Concentration by Inductively Coupled Plasma - Mass 
Spectrometry (ICP-MS) 
Parental MDA-MB-435 (430 x 103) cells, A-549 (500 x 103) cells and DU-145 
(550 xlOJ) cells were seeded in T-150 cm tissue culture flasks, maintained in 20 mL of 
either MEM or RPMI 1640 medium and allowed to grow for 3 days to obtain as 65 - 70% 
confluent cell population. After the incubation period, the cells were treated with the EC5o 
concentration of cisplatin, 4DB or 4TB for two hours. A control sample for each treatment 
group was treated with the drug vehicle, DMSO. The drug or DMSO is washed from each 
flask by rinsing three times with 20 mL of PBS. For the 4 and 24 hr time points, fresh 
medium was added to the flask and the cells were incubated for the stated time period. For 
the 0 hr time point, flasks were harvested immediately following the 2 hr drug treatment. 
At the indicated time points, cells were harvested, counted and separated into two aliquots, 
one aliquot contained 1.0 x 10 cells and was designated as the whole cell sample, the 
second aliquot contained the remaining volume of cell solution and was designated as the 
genomic sample. For clarification, cell samples designated as the 0 hr sample were 
exposed to drug for 2 hr, washed, then immediately harvested. Samples designated as 4 hr 
or 24 hr were exposed to drug for 2 hr, washed, then incubated in fresh medium for 4 hr or 
24 hr, respectively. 
The cell solutions were centrifuged at 4° C for 5 min at 2000x g, and the resulting 
supernatant was discarded. The remaining cell pellet was washed three times using the 
following process: resuspend the cell pellet in 500 uL of cold PBS and centrifuge at 4 °C 
for 5 min at 2000x g, and discard the resulting supernatant. After the final wash, 75 uL of 
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PBS was added for a total volume of 100 uL. The samples were then stored at -70 °C until 
further analysis. 
The samples designated as whole cell were lysed using 200 uL of M-PER (Pierce) 
containing 20 uL/mL Protease Inhibitor (Pierce) and 10 uL/mL EDTA (Pierce). The 
sample was gently vortexed at room temperature for 5 min then centrifuged at 14,000 x g 
for 15 min at 4° C to pellet the cell debris. A total of 30 uL of supernatant was removed 
for protein quantification using the bicinchoninic acid protein assay (Pierce) and the 
remaining sample was returned to the -70 °C freezer until digestion and subsequent ICP-
MS analysis. The sample designated as the genomic extract was subjected to the DNA 
extraction procedure described previously. The resulting solution was separated into two 
aliquots, one for quantification and one for ICP-MS analysis. Quantification of the sample 
is conducted immediately using the ND-1000 as described previously. The sample 
designated for ICP-MS analysis was returned to the -70 °C freezer until digestion and 
subsequent ICP-MS analysis. 
Prior to digestion, the volume of each sample was recorded. Samples were then 
digested by adding a total of 143 uL of 70% trace grade nitric acid (Fluka, USA) to the 
sample. The open vessels were placed in a 70 °C heat block and were heated for 90 min. 
While continuing to heat, 20 uL of 30% hydrogen peroxide (Sigma-Aldrich, USA) was 
added to each sample. Heating was continued for an additional 3.5 hr for a total digestion 
period of 5 hr. Samples were then filtered using a syringe (Becton Dickinson) with an 
attached 0.45 um polyethersulfone membrane syringe filter (VWR, USA). The total 
volume of the sample wass brought to 10 mL and the final sample mass was determined 
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and recorded. Terbium was added to each sample such that the final concentration was 1 
ppb to serve as the internal standard during analysis. 
External platinum standards at concentrations of 20, 10, 5, 1 and 0.05 ppb were 
prepared gravimetrically by diluting the stock 1000 ppm platinum standard 
(Environmental Express, Mt. Pleasant, SC, USA) in 1% trace grade nitric acid (Fluka). 
Platinum standards for the purpose of continuous calibration verification were prepared 
gravimetrically by diluting the stock 1000 ppm platinum standard (High Purity Standards, 
Charleston, SC, USA) in 1% trace grade nitric acid (Fluka) to 10 and 5 ppb. The blank 
used during analysis was 1 % trace grade nitric acid (Fluka). The digested samples were 
nebulized into the ICP-MS instrument without further dilution. 
The following calculations were employed using the data generated from the 
aforementioned experiments: 
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% Whole Cell Uptake 
% Drug Bound to DNA = 
pgPt'HS Protein = 
Concentration of Pt (ppb), 0 hr Whole Cell Sample 
Concentration of Pt (ppb) in the EC$o Concentration 
Concentration of Pt (ppb), 0 hr Genomic Sample 
Concentration of Pt (ppb) in theECjo Concentration 
Mass of Pt (pg) in Respective Whole Cell Sample 
Mass of Protein (u?) in Respective Whole Cell Sample 
x 100% 
x i00% 
pgPt/HgDNA= 
Mass of Pt (pg) in Respective Genomic Sample 
Mass of DNA (fig) in Respective Genomic Sample 
% Intracellular Pt Remaining = 
pgPt / ng Protein in Respective Whole Cell Sample 
p g Pt / ng Protein in 0 hr Whole C ell Sample x l00% 
% Pt-DNA Adducts Remaining 
pgPt / Hg DNA in Respective Genomic Sample 
pgPt/ ngDNAin 0 br Genomic Sample 
xl00<! 
3.17 Statistical Analysis 
Results were expressed as mean ± standard deviation (SD), with groups consisting 
of three observations and each experiment was preformed two or three times. Graph 
Pad Quick Calcs (www.graphpad.com) was used for Student's t test. P values less 
than 0.05 were considered significant. All graphical error bars are representative of 
standard deviation measurements. 
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CHAPTER 4 
FINDINGS OF THE STUDY 
4.1 Analysis of Results 
The focus of the study is to determine the cause of varying responses to cisplatin 
and novel cisplatin analogues between different tissue types. Previous studies (Vo, 
2009 ) discovered that the EC5o for the 4TB analogue varied by a factor of 40 between 
breast (MDA-MB-435), prostate (DU-145) and lung (A-549) cancer cell lines. The 
EC5o values determined by clonogenic survival are summarized in Table 1. Given that 
these values were the focus of this study, the first step in the research process was to 
ensure that the EC50 values could be duplicated by a different researcher. 
Agent (uM) 
Cisplatin 
4DB 
4TB 
A549 
850 
8.50 ±0.56* 
>100 
DU-145 
490.00 ±169.71 
2.53 ± 0.29 * 
73.72 ±36.21 * 
MDA-MB-435 
311.96 ±57.31 
2.50 ±0.33 * 
2.41 ± 1.03 * 
Table 1: EC50 values determined by Vo using the clonogenic survival assay method. 
* Statistically significant in comparison to cisplatin. 
38 
Clonogenic survivals using cisplatin, 4DB and 4TB with MDA-MB-435, A-549 
or DU-145 cells are shown in Figures 10A, 10B and IOC, respectively. The cells were 
exposed to varying concentrations of each drug for 1 h. The calculated EC50 values from 
the experiments conducted for the current study are given in Table 2. The values obtained 
in the current study are equivalent to those obtained by Vo, and the trends of the data 
with respect to the lethality induced by each drug is consistent with the previous findings. 
The results from these initial clonogenic survival experiments supported further work in 
determining the factors responsible for the observed cytotoxicity induced by each drug in 
these different cell lines. 
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Figure 10: Clonogenic survival using cisplatin, 4DB or 4TB in MDA-MB-435 (A), A-
549 (B) or DU-145 (C) cells. Cell survival was measured and compared to control cells 
after a 1 hr exposure to varying concentrations of the indicated drug. The above figures 
represent three trials each. Colonies were stained with crystal violet and viability was 
measured by counting colonies and comparing to the number of colonies in the control 
sample. A colony is a group of cells with n >50. 
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Agent (|nM) 
Cisplatin 
4DB 
4TB 
A549 
900 ± 4.28 
9.41 ± 2.79 * 
>100 
DU-145 
490.00 ±15.20 
1.85 ±0.089* 
79.10 ±18.41* 
MDA-MB-435 
523 ±13.79 
1.33 ±0.34* 
3.65 ± 0.82* 
Table 2: EC50 values determined in the current study using the clo no genie survival 
assay method. * Statistically significant in comparison to cisplatin. 
In addition to confirming the previous clonogenic survival data, the established EC50 
values were confirmed as an efficacious dose to test the rate of platinum-DNA adduct 
repair. Inductively coupled plasma-mass spectrometry (ICP-MS) analysis was employed 
to determine the concentration of drug taken up by the cells as well as rate of lesion 
repair. Initial protocol optimization required identifying the maximum number of cells 
that could be used to determine the rate of platinum-DNA (Pt-DNA) adduct repair for 
each cell line. Concentration of DNA is determined spectrophotometrically and is 
therefore subject to the Beer-Lambert Law. A standard curve of DNA mass verses cell 
number was constructed for each wild type cell line to ensure the concentration of DNA 
used in the ICP-MS studies could be accurately quantified. Wild type cells were seeded 
in T-150 cm2 tissue culture flasks and were allowed to grow uninterrupted for three days, 
at which time the population density reached 70 to 75% confluency. The cells were then 
harvested, counted, divided into aliquots of increasing cell number and then subjected to 
DNA extraction. The DNA binding columns used in the extraction process can 
accommodate up to 5 x 106 cells; therefore, cell numbers ranging from zero to 4.5 x 10 
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cells were used. The concentration of DNA in each sample was quantified using the 
NanoDrop ND-100 as described previously. These studies revealed that for all cell lines, 
the mass of DNA up to 4.5 x 106 cells falls within the linear range of the standard curve 
and can be accurately quantified (Figure 11). Therefore, 4.5 x 106 cells was the maximum 
number of cells used in any genomic sample in the ICP-MS studies. 
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r2 = 0 .9863 
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A-549 
y = 7 . 3 6 5 x + 0 .155 
r2 = 0 . 9 8 5 3 
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Figure 11: Standard curves of DNA mass verses cell number for MDA-MB-435 (A), A-
549 (B) and DU-145 (C) cells. The ordinate represents the mass of DNA in micrograms 
and the abscissa represents the total number of cells in the sample. Values are 
representative of three independent experiments. Error bars, when not visible, are smaller 
than the symbols representing the measurement. 
Another component of ICP-MS protocol optimization required determination of 
the total concentration of platinum that could potentially be present in the sample, but had 
not been taken up by the cells. In order to account for any residual platinum, "wash 
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controls" were analyzed for each cell line with each drug. The preparation of these 
samples involved exposing an equivalent cell population as a treatment sample to the 
same drug concentration for only 1 min, followed by the washing procedure described 
previously that was established for the treatment samples. The cells were then harvested, 
digested and analyzed for total platinum content by ICP-MS analysis. Total concentration 
of platinum remaining in comparison to total platinum concentration introduced yielded 
the percentage of platinum bound extracellularly which can then be subtracted from the 
total amount of platinum in the treatment samples. The results of the study, outlined in 
Table 3, revealed that the maximum concentration of platinum in the wash controls was 
0.0161 ppb which was present in the A-549 sample treated with the EC50 concentration of 
4TB. The values obtained from the study reveal that the amount of extracellular platinum 
present in the sample was effectively removed using the developed washing procedure 
after drug treatment. For comparison, the concentration of platinum in each drug 
concentration is provided in Table 4. 
Platinum 
(ppb) 
Cisplatin 
4DB 
4TB 
MDA-MB-435 
0.0088 
0.0081 
0.0137 
A-549 
0.0100 
0.0140 
0.0161 
DU-145 
0.0116 
0.0152 
0.0160 
Table 3: Concentration of platinum (ppb) in the wash control samples. 
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Platinum 
(ppbxlO3) 
Cisplatin 
4DB 
4TB 
MDA-MB-435 
60.84 
0.49 
0.47 
A-549 
165.75 
1.66 
19.50 
DU-145 
95.55 
0.49 
14.37 
Table 4: Concentrations of platinum (ppb x 10 ) present in the EC50 drug concentrations 
for each cell line. 
After confirming that the protocol for washing the cells following drug treatment 
was sufficient, protocol optimization for treatment samples was conducted. The A-549 
cell line and the 4DB drug were chosen as the model system. The identified variables in 
these experiments were the minimum number of cells to use for genomic samples, length 
of drug exposure, presence of an oxidizing agent during digestion, length of digestion and 
digestion temperature. A summary of the optimization process is provided in Table 5. As 
shown in Figure 12, obtaining repeatable results above the limit of detection (LOD) for 
the instrument required five different trials. Each trial had three treatment samples at each 
time point. The protocol provided in the Experimental Procedures section outlines the 
final, optimized protocol for ICP-MS analysis. 
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Trial 
1 
2 
3 
4 
5 
Drug 
Exposure 
lh r 
lh r 
lh r 
3hr 
2hr 
Cell Number in the 
Genomic Extract (GE) 
650,000 
2.0 x 106 
2.5 x 106 
725,000 
2.5 x 106 
Digestion 
1 hr at 70 °C, 
no oxidizing 
agent 
1 hr at 70 °C, 
no oxidizing 
agent 
2 hr at 95 °C, 
no oxidizing 
agent 
5 hr at 70 °C, 
no oxidizing 
agent 
5 hr at 70 °C, 
15%H202 
Results 
Platinum levels were above 
the LOD for the genomic 
samples; however, the 
standard deviation between 
trials was unacceptable. 
Platinum levels were above 
the LOD for the genomic 
samples; however, the 
standard deviation between 
trials was unacceptable. 
Platinum levels were above 
the LOD for the genomic 
samples; however, the 
standard deviation between 
trials was unacceptable. 
Platinum levels were below 
the LOD for the genomic 
samples; increased drug 
exposure decreased the 
number of cells in each 
sample. 
Platinum levels were above 
the LOD for the genomic 
samples; acceptable standard 
deviation between trials. 
Table 5: Summary of the protocol used and the results obtained from the optimization 
experiments for ICP-MS analysis using the A-549 cell with the 4DB drug as the model 
system. 
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Figurel2: Results of ICP-MS optimization trials 1 (A), 2 (B), 3 (C) and 5 (D) using A-
549 and the respective EC5o concentration of 4DB. No data is shown for trial 4 per levels 
of platinum were below the limits of detection for the instrument. Values are 
representative of three independent experiments for each time point within each trial, and 
error bars are representative of standard deviation. 
After optimizing the protocol for ICP-MS analysis, experiments were conducted 
with the MDA-MB-435, A-549 and DU-145 cell lines using the established EC50 
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concentrations of cisplatin, 4DB and 4TB. Each cell line was exposed to the indicated 
drug for 2 hr, followed by washing then harvesting at the indicated time point. 
Samples were analyzed for whole cell uptake of each drug by determining the 
concentration of platinum present in whole cells compared to the concentration of 
platinum in the EC5o concentration immediately following drug exposure. Results are 
reported as a percentage of platinum taken up by the cell. The clearance rate of each drug 
was determined by analyzing the whole cell samples at 4 hr and 24 hr post drug exposure. 
The amount of drug that gained access to the DNA was determined by measuring the 
percentage of platinum present in the extracted DNA at the 0 hr time point compared to 
the concentration of platinum in the EC50 concentration (Table 4). 
Analysis of whole cell uptake for each cell line revealed that the drugs that were 
the most lethal were uniformly taken up by the cells at higher concentrations than the less 
efficacious drugs. As shown in Figure 13A, MDA-MB-435 cells had taken up 0.16% of 
cisplatin, 8.11% of 4TB and 23.25% of 4DB; A-549 cells had taken up 0.27% of 
cisplatin, 0.08% of 4TB and 4.24% of 4DB; DU-145 cells had taken up 0.15% of 
cisplatin, 2.70% of 4TB and 29.65% 4DB. 
Analysis of genomic extracts for platinum revealed that there was an increase in 
the amount of Pt-DNA adducts formed immediately following drug treatment in the 
drugs that induced the highest level of cytotoxicity compared to the drugs that were less 
cytotoxic. As shown in Figure 13B, the percentage of the 4DB drug within the cell that 
formed Pt-DNA adducts was significantly increased in comparison to drugs that were less 
lethal. In the MDA-MB-435 cell line the percentage of drug that had formed Pt-DNA 
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adducts was 0.0093% with cisplatin, 0.21% with 4TB and 0.41% with 4DB. In the A-549 
cell line, the percentage of drug that had formed Pt-DNA adducts was 0.17% with 
cisplatin, 0.0074% with 4TB and 0.98% with 4DB. In the DU-145 cell line, the 
percentage of drug that had formed Pt-DNA adducts was 0.0065% with cisplatin, 0.018% 
with 4TB and 0.27% with 4DB. 
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Figure 13: ICP-MS analysis of the percentage of drug uptake in whole cells and genomic 
extracts in wild type MDA-MB-435, A-549 and DU-145 cells. Panel A represents the 
percentage of the platinum remaining in whole cells immediately following drug 
treatment. Panel B represents the percentage of the platinum remaining in the genomic 
extracts immediately following drug treatment. 
To confirm both the ability of the cell to export the drug and repair the formation 
of Pt-DNA adducts, the mass of platinum per mass of protein or DNA over time was 
determined. As shown in Figure 14, the mass of platinum per mass of protein for all cell 
lines with all drugs correlates to the given mass of platinum in each EC50 concentration. 
Control samples represent exposure to the drug vehicle, DMSO, for 2 hr. The data also 
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shows that over time, all cell lines have the capacity to export the drug from the cell. 
With respect to the MDA-MB-435 cell line and the 4DB drug, the initial uptake of drug 
was 4332 pg Pt/ug protein which decreased over time to 3311 pg Pt/ug protein at 4 hr 
and 883 pg Pt/ug of protein at 24 hr post drug treatment. For the same cell line with the 
4TB drug, uptake was determined to be 1472, 1032, and 566 pg Pt/ug protein at 0, 4 and 
24 hr, respectively. Treatment with cisplatin yielded uptake values of 5118, 4064 and 
1510 pg Pt/ug protein at 0, 4 and 24 hr, respectively. Given that the EC50 concentration 
was the highest for cisplatin, then 4DB, then 4TB, the values of platinum per mass of 
protein correlate to the amount of platinum exposure. The data reveals that there were 
greater amounts of platinum in the cisplatin samples than the 4DB or 4TB samples. 
In the A-549 cell line, treatment with 4DB yielded uptake values of 4322, 3311 
and 883 pg Pt/ug protein at 0, 4 and 24 hr, respectively. Treatment in the A-549 cell line 
with 4TB yielded uptake values of 1472, 1032 and 556 pg Pt/ ug protein at 0, 4 and 24 
hr, respectively. Treatment with cisplatin yielded uptake values of 5118, 4064 and 1510 
pg Pt/ ug protein at 0, 4 and 24 hr, respectively. 
In the DU-145 cell line, treatment with 4DB yielded uptake values of 7001, 6201 
and 1348 pg Pt/ug protein at 0, 4 and 24 hr, respectively. Treatments with 4TB yielded 
uptake values of 16470, 14214 and 3904 pg Pt/ug protein at 0, 4 and 24 hr, respectively. 
Treatments with cisplatin in the DU-145 cell line yielded uptake values of 16255, 11219 
and 4049 pg Pt/ug protein at 0, 4 and 24 hr, respectively. 
50 
jffffff SSSfff SfSfjff 
Sample 
2 
S 3 A-549, 4DB 
^ A-549, 47B 
C n A-549, CDDP 
I , 
i 
ssssss ssssss jfssfjff 
<*v*v>yv ^ *v>y *v*vvy 
Sample 
Figure 14: Mass of platinum per mass of protein in MDA-MB-435 (A), A-549 (B) or 
DU-145 (C) cells over time following exposure to the EC50 concentration of the indicated 
drug. Values are representative of three independent experiments. 
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The trends observed in clearance of platinum from the whole cell were also 
observed in the removal of Pt-DNA adducts in each cell line with each drug. Control 
samples represent exposure to the drug vehicle, DMSO, for 2 hr. Rate of Pt-DNA adduct 
repair was determined by analyzing DNA extracts for concentration of platinum at 4 hr 
and 24 hr post drug exposure. As shown in Figure 15, the amount of Pt-DNA adducts is 
reduced over time and the amount of Pt-DNA adducts correlates to the original mass of 
platinum in the EC50 concentration for each drug in all cell lines. For example, with the 
MDA-MB-435 cell line, the EC50 concentration for cisplatin is 311 uM verses 2.41 uM 
with the 4TB drug. There were a greater number of Pt-DNA adducts formed in the 
cisplatin sample verses the 4DB samples. However, this trend was not unexpected given 
the drug concentrations used in the study. Specifically, in the MDA-MB-435 cell line, 
treatment with 4DB resulted in the formation of adducts in the amount of 795, 538 and 
105 pg Pt/ug DNA at 0, 4 and 24 hr, respectively. Treatment with 4TB resulted in the 
formation of adducts in the amount of 447, 239 and 206 pg Pt/ug DNA at 0, 4 and 24 hr, 
respectively. Treatment with cisplatin resulted in the formation of adducts in the amount 
of 2611, 1485 and 1069 pg Pt/ug DNA at 0, 4 and 24 hr, respectively. 
In the A-549 cell line, treatment with 4DB resulted in the formation of adducts in 
the amount of 795, 538 and 379 pg Pt/ug DNA at 0, 4 and 24 hr, respectively. Treatment 
in the A-549 cell line with 4TB resulted in the formation of adducts in the amount of 447, 
239 and 206 pg Pt/ug DNA at 0, 4 and 24 hr, respectively. Treatment with cisplatin 
resulted in the formation of adducts in the amount of 2611, 1485 and 1069 pg Pt/ug DNA 
at 0, 4 and 24 hr, respectively. 
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In the DU-145 cell line, treatment with 4DB resulted in the formation of adducts 
in the amount of 792, 739 and 622 pg Pt/ug DNA at 0, 4 and 24 hr, respectively. 
Treatment with 4TB resulted in the formation of adducts in the amount of 1808, 1673 and 
905 pg Pt/ug DNA at 0, 4 and 24 hr, respectively. 
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Figure 15: Mass of platinum per mass of DNA in MDA-MB-435 (A), A-549 (B) or DU-
145 (C) cells over time following exposure to the EC50 concentration of the indicated 
drug. Values are representative of three independent experiments. 
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In order to determine the rate of drug removal from the cells, the samples were 
analyzed for total mass of platinum verses total mass of protein. As described previously, 
cells were exposed to the drug then harvested at the indicated time point. Mass of protein 
in each sample was determined using the BCA assay. The mass of platinum in the 
original EC50 concentration varied for each drug; therefore, in order to make a direct 
comparison with respect to rates of drug clearance between the three drugs within each 
cell line, the mass of platinum in picogram per microgram of protein in the 0 hr sample 
was calculated and considered as 100%. The subsequent time points at 4 hr and 24 hr 
were calculated in the same manner and compared to the value obtained for the 0 hr time 
point. The percentage of platinum remaining for MDA-MB-435, A-549 and DU-145 are 
shown in Figure 16. In the MDA-MB-435 cells treated with 4DB only 8% of the drug 
had been cleared at the 4 hr time compared to 23% clearance for 4TB and 21% clearance 
for cisplatin. At 24 hr post drug exposure, 64% of the drug had been cleared from whole 
cells with respect to 4DB and 4TB whereas 72% of cisplatin had been removed. With 
respect to the A-549 cell line, at 4 hr post drug treatment the clearance rates for 4DB, 
4TB and cisplatin were 19%, 45% and 26%, respectively. The amount of drug cleared 
from the cells 24 hr post drug treatment for 4DB, 4TB and cisplatin were 53%, 57% and 
70%, respectively. In the DU-145 cell line, at 4hr post drug treatment, the clearance rates 
for 4DB, 4TB and cisplatin were 11%, 6% and 32%, respectively. At 24 hr post drug 
treatment, the clearance rates in the DU-145 cell line for 4DB, 4TB and cisplatin were 
71 %, 76% and 75% respectively. 
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Figure 16: ICP-MS analysis of the percentage of drug remaining in whole MDA-MB-
435 (A), A-549 (B) or DU-145 (C) cells over time following exposure to the EC50 
concentration of 4DB, 4TB or cisplatin. Values are representative of three 
independent experiments. * Statistically significant in comparison to cisplatin. 
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In order to determine the rate of Pt-DNA adduct repair, the samples were analyzed for 
total mass of platinum versus total mass of DNA. As described previously, cells were 
exposed to the drug then harvested at the indicated time point. Mass of DNA in each 
sample was determined by extracting the DNA using the GenElute kit and quantifying 
the DNA using the NanoDrop ND-1000 spectrophotometer. In order to make a direct 
comparison with respect to rates of Pt-DNA adduct repair between the three drugs within 
each cell line, the mass of platinum in picogram per microgram of DNA in the 0 hr 
sample was calculated and considered as 100%. The subsequent time points at 4 hr and 
24 hr were calculated in the same manner and compared to the value obtained for the 0 hr 
time point. The percentage of platinum bound to DNA that remains over time for MDA-
MB-435, A-549 and DU-145 cells are shown in Figure 17. Treating with 4DB in the 
MDA-MB-435 cell line revealed that only 33% of the lesions had been repaired 
compared to 47% repair for 4TB and 49% repair for cisplatin. At 24 hr post drug 
exposure, 52% of the adducts had been repaired with respect to 4DB and 4TB whereas 
70% of adducts in the cisplatin treatment group had been repaired. With respect to the A-
549 cell line, at 4 hr post drug treatment the repair rates for 4DB, 4TB and cisplatin were 
37%, 64%o and 55%, respectively. At the 24 hr time point, the percentage of lesions that 
had been repaired for 4DB, 4TB and cisplatin were 40%, 78% and 66%, respectively. In 
the DU-145 cell line, at 4hr post drug treatment, the percentage of adduct repair for 4DB, 
4TB and cisplatin was 7%, 16% and 35%, respectively. At the 24 hr time point, the 
percentage of lesions that had been repaired for 4DB, 4TB and cisplatin were 20%, 38% 
and 44%, respectively. 
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Figure 17: ICP-MS analysis of the percentage of drug remaining as Pt-DNA adducts in 
MDA-MB-435 (A), A-549 (B) or DU-145 (C) cells over time following exposure to the 
EC50 concentration of 4DB, 4TB or cisplatin. Values are representative of three 
independent experiments. * Statistically significant in comparison to cisplatin. 
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Microarray analysis was employed to determine if the cytotoxicity of each drug 
within each cell line could be accounted for by changes in gene expression following 
drug exposure. MDA-MB-435, A-549 and DU-145 cell lines were exposed to each drug 
for 1 hr and then the drug was removed. A 1 hr exposure to DMSO for each cell line was 
used as the control sample. Cells were harvested and the RNA was extracted at 0 hr, 4hr 
or 24 hr post drug exposure. The RNA samples were analyzed by the Windber Research 
Institute (Windber, PA, USA) for gene expression changes as a result of exposure to each 
drug. In order to determine the genes that had significant changes in the level of 
expression, the 0 hr sample was compared to the control sample and the 4 and 24 hr 
samples were then compared to the 0 hr sample. The genes with the greatest change in 
protein expression, up to five, were identified for each drug and each cell line. 
Unfortunately, RNA samples for the MDA-MB-435 cell line treated with 4DB at 
the 24 hr time point were too degraded for microarray analysis. The research staff at 
Windber Research Institute suggested that the reason the RNA was too degraded for 
analysis was due to the majority of the cells actively undergoing apoptosis. The research 
staff further suggested that it would be appropriate to analyze the MDA-MB-435 samples 
treated with 4DB at 0 hr, 2 hr and 4 hr post drug exposure for gene expression changes. 
Therefore, for the MDA-MB-435 cell line, samples treated with 4DB were analyzed at 2 
hr and 4 hr post drug exposure instead of 4 hr and 24 hr post drug exposure. In order to 
confirm that the reason the RNA was too degraded at this time point due to cell death, 
fluorescent microscopy and flow cytometry analysis were employed. In the fluorescent 
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microscopy experiments, cells were exposed to the EC50 concentration of 4DB for one 
hour. The control sample was exposed to DMSO for 1 hr. Following treatment, the drug 
is removed from the cells and the samples were then incubated for 0, 2, 4 or 24 hr prior to 
obtaining images. At the indicated time point, the samples were stained with 1 ug/mL 
Hoescht and 5 |ug/mL propidium iodide. After a 15 min exposure to the stain, the images 
were acquired. As shown in Figure 18, fluorescent microscopy analysis revealed that at 
the 4 hr time point, 28.7% of the cell population was undergoing apoptosis and 70.9% of 
the population was undergoing necrosis. These data reveal that 4 hr following drug 
treatment 99.6% of the population are in active stages of death. The experiment further 
revealed that at the 24 hr time point, 4.8% of the population was undergoing apoptosis 
and 25.5% of the population was undergoing necrosis. 
% Apoptosis 
% Necrosis 
control 0 hour 2 hour 4 hour 24 hour 
Time Following Treatment 
Figure 18: Fluorescent microscopy analysis of MDA-MB-435 cells exposed to the EC50 
concentration of 4DB. Values are representative of two independent experiments. 
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Flow cytometry analysis of cell cycle distribution in the MDA-MB-435 cells 
following treatment with 4DB was also conducted. The cells were exposed to the EC5o 
concentration of 4DB for 1 hr and the control sample was exposed to DMSO. Following 
drug exposure, the cells were washed and fresh medium was then added. The cells were 
incubated for 0, 2, 4 or 24 hr following exposure at which time they were harvested, 
pelleted and stained with 5 ug/mL propidium iodide. The samples were then analyzed as 
described previously using the flow cytometer. As shown in Figure 19, the data from the 
experiment revealed that at the 4 hr time point, approximately 48.3% of the cells were 
undergoing apoptosis and 64.7% of the cells were undergoing necrosis. These data reveal 
that 4 hr following drug treatment approximately 99% of the population are in active 
stages of death. The experiment further revealed that at the 24 hr time point, 6.6% of the 
population was undergoing apoptosis and 7.9% of the population was undergoing 
necrosis. Although the data from the fluorescent microscopy and flow cytometry 
experiments appear to suggest a decrease in cell death from the 4 hr to the 24 hr time 
point, the number of cells remaining at the 24 hr time point was extremely sparse given 
that the majority of the population was lost to cell death at the 4 hr time point. Therefore, 
these studies support the use of a 2 hr and 4 hr time point in the microarray analysis of 
MDA-MB-435 cells treated with the 4DB drug and removal of the 24 hr time point due to 
the inability to obtain pure RNA at 24 hr time point. 
61 
control 0 hour 2 hour 4 hour 24 hour 
| Hours Following Treatment I 
Figure 19: Flow cytometry analysis of apoptotic and necrotic events of MDA-MB-435 
cells exposed to the EC5o concentration of 4DB. Values are representative of two 
independent experiments. 
The five genes with the greatest change in expression were identified by 
microarray analysis as described previously. Tables 6 through 14 provide the genes of 
interest for the MDA-MB-435, A-549 and DU-145 cells lines following treatment with 
4DB, 4TB or cisplatin. A total of 93 genes were found to have increases in expression of 
at least three fold in response to the drug treatments. Of these 93 genes, 18 were found to 
occur in all three cell lines and all three drugs. One of the genes that was present in each 
cell line following treatment with 4DB was the CHOP gene which is a DNA damage 
inducible transcript which regulates progression through the cell cycle. Increased 
expression levels of this gene may play a role in decreased survival in all cell lines 
following treatment with 4DB due to the ability of CHOP to induce increased apoptotic 
signalling. Five of the 18 common genes were heat shock proteins, which have the 
62 
potential to lend protection against the cytotoxic effects of the drugs. Specifically, these 
heat shock proteins were HSP72, HSP70, HSP60, HSP40 and HSP32. 
In addition to finding genes in common between the cell lines and treatment 
groups, identifying over expressed genes in the DU-145 and A-549 cell lines following 
treatment with 4TB that were not present in the MDA-MB-435 cell line was also of 
interest. The A-549 cell line is completely non-responsive to 4TB, and the drug has 
limited efficacy, compared to the MDA-MB-435 cell line, in the DU-145 cell line. 
Therefore, if varying genes can be found in the different cell lines, this information would 
allow identification of genes that potentially contribute to the observed cytotoxicity. After 
analyzing the genes present in each treatment group, three genes were identified that were 
common to both A-549 and DU-145 but absent from MDA-MB-435. These genes were 
identified as ZNT1, p21 and metallothionein 1L. The ZNTR1 gene is responsible for 
cation and drug uptake in the cell. The over expression of this gene in the A-549 and DU-
145 cells versus no expression change in MDA-MB-435 cells may be a promising target 
in the examination of resistance to the 4TB drug. The data further revealed that 
metallothionein and p21 were over expressed following drug treatment in A-549 and DU-
145 cells, but were not over expressed in the MDA-MB-435 cells. Metallothionein is of 
interest because this protein has been shown to bind heavy metals, such as platinum and 
provide protection against heavy metals toxicity as well as oxidative stress. The p21 gene 
is responsible for cell cycle regulation and acts as an inhibitor of apoptosis. 
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Table 6: Microarray analysis of MDA-MB-435 cells treated with 4DB. The table above 
provides up to five genes at each compared time point that exhibited the greatest change 
in expression. 
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Table 7: Microarray analysis of MDA-MB-435 cells treated with 4TB. The table above 
provides up to five genes at each compared time point that exhibited the greatest change 
in expression. 
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Table 8: Microarray analysis of MDA-MB-435 cells treated with Cisplatin. The table 
above provides up to five genes at each compared time point that exhibited the greatest 
change in expression 
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Table 9: Microarray analysis of A-549 cells treated with 4DB. The table above provides 
up to five genes at each compared time point that exhibited the greatest change in 
expression. 
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Table 10: Microarray analysis of A-549 cells treated with 4TB. The table above provides 
up to five genes at each compared time point that exhibited the greatest change in 
expression. 
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Table 11: Microarray analysis of A-549 cells treated with Cisplatin. The table above 
provides up to five genes at each compared time point that exhibited the greatest change 
in expression. 
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brane 
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thrombomo 
dulin 
MT-11 
metallothio 
nein 1L 
(MT1L) 
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hepatic 
angiopoieti 
n-related 
protein 
GMCSF 
Granulocyt 
e-
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stimulating 
factor 
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metallothio 
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1 
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interleukin 
11 
0hr ,4 
hr 
0hr ,4 
hr 
Ohr, 24 
hr 
Ohr, 24 
hr 
Ohr, 24 
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hr 
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binding 
response to metal 
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cellular response to 
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cellular defence 
response 
response to metal 
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binding, 
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Enzyme inhibitor 
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cell surface 
receptor linked 
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granulocyte 
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binding 
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dase activity 
interleukin-11 
receptor binding, 
growth factor 
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Cytokine-
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receptor 
interaction, 
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killer cell 
mediated 
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N/A 
PPAR 
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Table 12: Microarray analysis of DU-145 cells treated with 4DB. The table above 
provides up to five genes at each compared time point that exhibited the greatest change 
in expression. 
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Table 13: Microarray analysis of DU-145 cells treated with 4TB. The table above 
provides up to five genes at each compared time point that exhibited the greatest change 
in expression. 
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Table 14: Microarray analysis of DU-145 cells treated with Cisplatin. The table above 
provides up to five genes at each compared time point that exhibited the greatest change 
in expression. 
The final phase of the project employed disruption of DNA repair mechanisms 
using shRNA to determine if the efficacy of the drugs could be improved in each of the 
cell lines. The proteins involved in the rate limiting steps of both the NER and MMR 
processes were selected as targets for suppression of DNA repair activity. However, prior 
to beginning studies with shRNA, confirmation of ERCC1 and MSH2 protein expression 
in the wild type cell line was confirmed. As shown in Figure 20, Western blot analysis 
revealed that both MSH2 and ERCC1 can be successfully probed for using this 
technique. Nuclear HeLa extract, known to express both these proteins, was used as a 
positive control and /3-actin was used as a loading control in the experiment. 
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Figure 20: Western blot analysis for MSH2 (A), ERCC1 (B) and 0-Actin (C) in wild type 
MDA-MB-435, A-549 and DU-145 cells. HeLa nuclear extract was used as a positive 
control. Each lane was loaded with 20\ig of protein. 
Disruption of the NER mechanism was accomplished by introducing shRNA 
against ERCC1 whereas disruption of the MMR mechanism was accomplished by 
introducing shRNA against MSH2. Two negative controls were used for these studies. 
The first negative control was the expression vector, shown in Figure 21, was used to 
ensure that the transfection process did not significantly change the response of the cell 
line to treatment. The second negative control was the expression vector with an 
ineffective shRNA insert against green fluorescence protein (GFP). This ineffective 
shRNA was used as a negative control to ensure that the presence of a non-effective 
shRNA does not have an effect on non-targeted protein expression. 
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Figure 21: Expression vector for shRNA constructs. The negative control is the 
expression vector only, without a shRNA insert. 
Four different constructs, targeting non-overlapping sequences of the gene of 
interest, were tested to determine which was the most effective in silencing each protein 
target. Each construct was tested in each cell line using the transient transfection 
procedure described previously. Western blotting analysis was employed to determine 
which construct was the most effective in reducing protein expression. In the A-549 cell 
line, construct 67 was most effective in silencing ERCC1 and construct 27 was most 
effective in silencing MSH2 (Figure 22A). In the DU-145 cell line, construct 65 was the 
most effective in silencing ERCC1 and construct 27 was the most effective in silencing 
MSH2 (Figure 22B). Transient transfection with MSH2 and ERCC1 constructs in the 
MDA-MB-435 cell line did not reveal an obvious construct to select for protein silencing 
with either target (Figure 22C). 
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Figure 22: Results of Western blot analysis in wild type and transiently transfected A-549 
(A), DU-145 (B) and MDA-MB-435 (C) cells probed for MSH2 or ERCC1. Each lane is 
loaded with 30ug of protein. 
In order to effectively determine the appropriate constructs to use against each 
target, the stable transfection procedure was used for each target in the MDA-MB-435 
cell line. These cells were then subjected to intracellular antigen staining as described 
previously and analyzed using the flow cytometer. As shown in Figure 23A, the MSH2 
construct that resulted in the least amount of protein expression was construct 25. The 
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ERCC1 construct that resulted in the least amount of protein expression was construct 65, 
as shown in Figure 23B. Confirmation of the intracellular antigen staining results was 
achieved by repeating the Western blot analysis with all the stable transfects. As shown 
in Figure 24, Western blot and intracellular antigen staining experiments provide 
confirmation that construct 25 had the least amount of MSH2 expression whereas 
construct 65 had the least amount of ERCC1 expression. 
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Figure 23: Intracellular antigen staining of MDA-MB-435 cells for MSH2 (A) or ERCC1 
(B). 
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Figure 24: Western blot analysis of MDA-MB-435 stable transfects. Samples were 
probed for ERCCI, MSH2 or /8-Actin. Each lane was loaded with 30ug of protein. 
The selected constructs as well as positive and negative controls were used in the 
stable transfection procedure for all cell lines. The nomenclature for these newly 
developed cell lines utilized the beginning letter designation for each cell line, followed 
by the name of the target. The name of each cell line and its description are listed in 
Table 15. 
86 
Wild Type Cell 
Line 
A-549 
A-549 
A-549 
A-549 
DU-145 
DU-145 
DU-145 
DU-145 
MDA-MB-435 
MDA-MB-435 
MDA-MB-435 
MDA-MB-435 
Table 15: Nomenc 
Transfected Cell 
Line Name 
A-shEV 
A-shGFP 
A-shMSH2 
A-shERCCl 
DU-shEV 
DU-shGFP 
DU-shMSH2 
DU-shERCCl 
MB-shEV 
MB-shGFP 
MB-shMSH2 
MB-shERCCl 
Transfected Cell Line Description 
A-549 cell line transfected with the empty 
expression vector, negative control 
A-549 cell line transfected with ineffective 
shRNA against GFP, negative control 
A-549 cell line transfected with effective 
shRNA against MSH2, construct 27 
A-549 cell line transfected with effective 
shRNA against ERCC1, construct 67 
DU-145 cell line transfected with the empty 
expression vector, negative control 
DU-145 cell line transfected with 
ineffective shRNA against GFP, negative 
control 
DU-145 cell line transfected with effective 
shRNA against MSH2, construct 27 
DU-145 cell line transfected with effective 
shRNA against ERCC1, construct 65 
MDA-MB-435 cell line transfected with the 
empty expression vector, negative control 
MDA-MB-435 cell line transfected with 
ineffective shRNA against GFP, negative 
control 
MDA-MB-435 cell line transfected with 
effective shRNA against MSH2, construct 
25 
MDA-MB-435 cell line transfected with 
effective shRNA against ERCC1, construct 
65 
ature for cell lines expressing shRNA developed using stable 
transfection methods. 
After stable transfections of all cell lines were completed, Western blot analysis 
was again conducted to ensure that the silencing of the ERCC1 and MSH2 targets was 
effective. Included in the analysis were the wild type cell line and both negative controls 
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(shGFP and shEV). Results of the Western blot experiments, Figures 25, 26 and 27, 
revealed that in all cell lines the shGFP and shEV samples had equivalent levels of 
protein expression in comparison to the wild type sample. All cell lines that were 
transfected with shRNA against ERCC1 or MSH2 had reduced levels of the intended 
target in comparison to the wild type and control samples. 
WtlrfTvno Mft-shPV MHMifP MR-shFRrn ME-shMSM? 
MSH2 
ERCC1 
P-Actin 
Figure 25: Western blot analysis of wild type and stable transfects of the MDA-MB-435 
cell line. Samples were probed for MSH2, ERCC1 or /3-Actin. Each lane was loaded with 
30|ig of protein. 
Wild Type OU-shEV OU-shGFP DU-shERCCl DU-shMSH2 
«?5?K*5?Sfr 
MSH2 
ERCC1 
P-Actin 
igure 26: Western blot analysis of wild type and stable transfects of the DU-145 cell 
line. Samples were probed for MSH2, ERCC1 or /3-Actin. Each lane was loaded with 
30(ig of protein. 
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Figure 27: Western blot analysis of wild type and stable transfects of the A-549 cell line. 
Samples were probed for MSH2, ERCC1 or /3-Actin. Each lane was loaded with 30|ig of 
protein. 
After confirming that the developed cell lines had decreased expression levels of 
proteins of interest, clonogenic survivals with the shEV, shERCCl and shMSH2 
constructs for each cell line were conducted. The shGFP cell lines were not included in 
these studies because Western blot analysis confirmed that levels of protein expression 
did not change with the transfection of ineffective shRNA. As described previously, cells 
were exposed to varying concentrations of the indicated drug for 1 hr, washed, harvested, 
and then plated with the wild type control cell number. Cells were incubated for 10 days, 
stained with crystal violet and the resulting colonies were counted to determine survival. 
The EC5o values for each drug with each cell line were determined using the survival 
curves generated for the transfected cell lines. As shown in Figure 28, the only 
statistically significant difference, as compared to the related shEV and wild type cell 
lines, in the survivals conducted with the MDA-MB-435 transfected cell lines was 
observed in the MB-shMSH2 cell line upon exposure to 10" M cisplatin. 
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Figure 28: Clonogenic survival using cisplatin (A), 4DB (B) or 4TB (C) in MDA-MB-
435 transfected cells. Cell survival was measured and compared to control cells after a 1 
hr exposure to varying concentrations of the indicated drug. The above figures represent 
three trials each. Colonies were stained with crystal violet and viability was measured by 
counting colonies and comparing to the number of colonies in the control sample. A 
colony is a group of cells with n >50. 
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Similar results were obtained with the A-549 and DU-145 transfected cell lines. 
As shown in Figure 29, the only statistically significant difference, as compared to the 
related shEV and wild type cell lines, in the survivals conducted with the A-549 
transfected cell lines was observed in the A-shMSH2 cell line upon exposure to 10" M 
cisplatin. In the DU-145 transfected cell lines, as shown in Figure 30, the only 
statistically significant difference in survival, as compared to the related shEV and wild 
type cell lines, was observed in the DU-shERCCl cell line upon exposure to 10"4 M 4TB. 
The EC50 values for each transfected cell line with each drug are reported in Tables 16, 
17 and 18 for MDA-MB-435 transfected cells, A-549 transfected cells or DU-145 
transfected cells, respectively. These data suggest that the relative efficiencies of the 
DNA repair mechanisms cannot, on their own, account for the observed differences in 
lethality between the three investigated chemotherapeutic drugs. 
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Figure 29: Clonogenic survival using cisplatin (A), 4DB (B) or 4TB (C) in A-549 
transfected cells. Cell survival was measured and compared to control cells after a 1 hr 
exposure to varying concentrations of the indicated drug. The above figures represent 
three trials each. Colonies were stained with crystal violet and viability was measured by 
counting colonies and comparing to the number of colonies in the control sample. A 
colony is a group of cells with n >50. 
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Figure 30: Clonogenic survival using cisplatin (A), 4DB (B) or 4TB (C) in DU-145 
transfected cells. Cell survival was measured and compared to control cells after a 1 hr 
exposure to varying concentrations of the indicated drug. The above figures represent 
three trials each. Colonies were stained with crystal violet and viability was measured by 
counting colonies and comparing to the number of colonies in the control sample. A 
colony is a group of cells with n >50. 
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Agent 
(HM) 
CDDP 
4DB 
4TB 
Table 16: 
MDA-MB-435 
(Wild Type) 
311.96 
2.50 
2.41 
EC™ values determ 
MB-shEV 
400 
3.00 
7.32 
ined of MDA-MB-42 
MB-shERCCl 
402 
3.00 
1.85 
15 wild type and trar 
MB-shMSH2 
975* 
3.64 
2.62 
isfected cells as 
determined by using the clonogenic survival assay method. * Statistically significant in 
comparison to wild type and shEV cell line. 
Agent 
(uM) 
CDDP 
4DB 
4TB 
A-549 
(Wild Type) 
850 
8.50 
>100 
A-shEV 
1110 
1.33 
>100 
A-shERCCl 
930 
1.38 
>100 
A-shMSH2 
>1000* 
1.11 
>100 
Table 17: EC50 values determined of A-549 wild type and transfected cells as determined 
by using the clonogenic survival assay niethod. * Statistically significant in comparison to 
wild type and shEV cell line. 
Agent 
(uM) 
CDDP 
4DB 
4TB 
DU-145 
(Wild Type) 
490.00 
2.53 
73.72 
DU-shEV 
332 
3.54 
93.5 
DU-shERCCl 
309 
3.54 
25.2* 
DU-shMSH2 
375 
3.54 
51.3 
Table 18: EC50 values determined of DU-145 wild type and transfected cells as 
determined by using the clonogenic survival assay method. * Statistically significant in 
comparison to wild type and shEV cell line. 
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CHAPTER 5 
SUMMARY, CONCLUSIONS AND RECOMMENDATIONS 
5.1 Discussion of Results 
The purpose of the current study was to determine potential biomarkers and other 
factors inherent to the three investigated chemotherapeutic drugs that are responsible 
for the observed variations in lethality upon treatment with cisplatin 4DB and 4TB in 
different cancer tissue types. The current study generated data relevant to the 
following tasks: 
1) Characterize drug uptake and drug clearance over time in whole cells in wild 
type breast, prostate and lung cancer cell lines; 
2) Determine the levels of platinum-DNA adducts formed over time with each 
drug in all wild type cell lines; 
3) Determine by microarray analysis which genes are expressed in the wild type 
cell lines in response to drug treatment; 
4) Suppress DNA repair mechanisms, nucleotide excision repair and mismatch 
repair, using short hairpin RNA, to determine the effects on drug efficacy. 
Determination of drug uptake and clearance over time in the wild type cell lines 
was achieved by analyzing samples treated with the EC50 concentration of each drug 
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using ICP-MS analysis. Comparing the observed lethality of each drug to the level of 
initial drug uptake and subsequent clearance of drug from the cells can lend insight into 
whether or not drug uptake is playing a role in the ability of each drug to induce cell 
death. To determine the level of uptake, the initial concentration of platinum 
immediately following treatment was measured in each sample. The concentration in the 
sample was then compared to the total concentration of platinum in each EC50 
concentration. The concentration of platinum in the treatment sample was divided by the 
total concentration of platinum in the EC50 concentration to determine the percentage of 
drug uptake. The results revealed that percentage of drug uptake as well as percentage of 
drug clearance over a 24 hr period can be correlated to the level of lethality exerted by 
each drug in each cell line. As shown in Table 1, 4DB is the most lethal drug in all three 
cell lines investigated. The 4TB drug is effective in both the DU-145 and MDA-MB-435 
cell lines but had no effect in the A-549 cell line. Further, the 4TB drug is 30 times more 
lethal in the MDA-MB-435 cell line compared to the DU-145 cell line. With respect to 
cisplatin, the drug is effective in inducing cell death, but only at concentrations greater 
than 300 uM for all cell lines. Drug uptake studies with 4DB (Figure 13A) revealed that 
23.25%, 4.24% and 29.65% of the drug was taken up by MDA-MB-435, A-549 and DU-
145 cells, respectively. This trend continued in all cell lines with the other two 
investigated drugs, 4TB and cisplatin. Levels of drug uptake with 4TB were 8.11%, 
0.08% and 2.70% for the MDA-MB-435, A-549 and DU-145 cells, respectively. Levels 
of drug uptake with cisplatin were 0.16%, 0.27% and 0.15% for the MDA-MB-435, A-
549 and DU-145 cells, respectively. 
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Characterization of nuclear uptake of each drug, lends further support to the idea 
that the level of drug uptake positively correlates to cytotoxicity (Figure 13B). In the 
MDA-MB-435 cell line, the percentage of drug that had formed Pt-DNA adducts 
immediately following drug treatment was 0.0093% with cisplatin, 0.21% with 4TB and 
0.41% with 4DB. In the A-549 cell line, the percentage of drug that had formed Pt-DNA 
adducts was 0.17% with cisplatin, 0.0074% with 4TB and 0.083% with 4DB. In the DU-
145 cell line, the percentage of drug that had formed Pt-DNA adducts was 0.0065% with 
cisplatin, 0.018% with 4TB and 0.27% with 4DB. As with the whole cell platinum 
accumulation studies, the drugs that induce the highest levels of cytotoxicity also formed 
the greatest number of Pt-DNA adducts. These data show a positive correlation between 
Pt-DNA adduct formation and drug lethality. 
ICP-MS studies of drug clearance rates also provided insight into the factors that 
contribute to the observed lethality with each drug. Samples were first analyzed to 
determine if each cell line was competent to both export the drug from the cell as well as 
repair Pt-DNA adducts. These studies confirmed that levels of platinum in whole cells as 
well as levels of Pt-DNA adducts decreased over time with respect to all cell lines and all 
drugs (Figures 14 and 15). Analysis of drug clearance rates from whole cells revealed 
that the more efficacious drugs (i.e., lower EC5o concentration) were retained at higher 
concentrations in the cell during the 24 hr period in comparison to the drugs that were 
less effective at inducing cell kill. Specifically, in MDA-MB-435 cell line, 36% of both 
4DB and 4TB remained in the cells 24 hr post treatment. Given that the EC50 
concentrations for 4DB and 4TB with the MDA-MB-435 cell line are nearly identical, 
97 
and the clearance rates of these drugs are also identical, the data suggests that the ability 
of the cell to export the drug is directly related to its lethality. The studies with MDA-
MB-435 further showed that only 28% of cisplatin remained after a 24 hr period (Figure 
16A). In the A-549 cell line, the amount of each drug remaining 24 hr following 
treatment for 4DB, 4TB and cisplatin were 47%, 43% and 30%, respectively. The data 
for the A-549 cell line (Figure 16B) with respect to 4DB and cisplatin correlate to the 
given EC50 values for each of these drugs. However, the clearance rate for 4TB does not 
correlate to the established EC50 value. The amount of drug remaining 24 hr post drug 
treatment in DU-145 cells was 29%, 24% and 25% for 4DB, 4TB and cisplatin, 
respectively (Figure 16C). The studies involving drug uptake and clearance reveal that if 
an increased concentration of drug gains access to and remains in the cell, the more lethal 
the drug. These data show that in order for newer generation of cisplatin analogues to 
have the desired efficacy, the drug must effectively gain access to and be retained with 
the cell. 
The second primary task in the current study was to determine the level of 
platinum-DNA adducts formed over time with each drug type in all wild type cell lines. 
ICP-MS studies of platinum present in genomic extracts of cells treated with the EC50 
concentration of each drug revealed that the drugs with increased levels of uptake also 
had increased levels of Pt-DNA adduct formation. The studies further showed that the 
more efficacious drugs had reduced levels of repair in comparison to the drugs with 
reduced efficacy. Specifically, in the MDA-MB-435 cell line, the percentage of lesions 
remaining in both the 4DB and 4TB treated samples 24 hr post drug exposure was 48% 
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compared to only 30% of the lesions remaining in the samples treated with cisplatin 
(Figure 17A). There is a correlation between drug cytotoxicity and ineffective repair of 
Pt-DNA adducts. This correlation was also observed in the A-549 and DU-145 cell lines. 
In the A-549 cell line, the percentage of lesions remaining 24 hr post drug treatment were 
63% in 4DB treatment samples, 36% in 4TB treatment samples and 45% in samples 
treated with cisplatin (Figure 17B). In the DU-145 cell line, the percentage of lesions 
remaining 24 hr post drug treatment were 80% in 4DB treatment samples, 72% in 4TB 
treatment samples, and 56% in cisplatin treatment samples (Figure 17C). 
The data obtained from the analysis of Pt-DNA adduct clearance from cells 
suggests that effective repair of Pt-DNA adducts correlates to increased survival. These 
data lend further insight into the method by which these drugs exert their cytotoxic 
effects once inside the cell. Further, the analyses of Pt-DNA adduct clearance with the 
4TB drug in the A-549 cells indicate that although 43% of the drug remains in the cell 24 
hr post drug treatment, only 36% of the Pt-DNA adducts remained. The amount of Pt-
DNA adducts remaining is consistent with drugs that are less efficacious in other cell 
lines. For example, cisplatin is the least efficacious of the three investigated drugs in the 
DU-145 cell line with 56% of Pt-DNA adducts remained 24 hr post drug treatment. 
These data reveal that chemotherapeutic drugs that have the capacity to thwart DNA 
repair processes have the potential to induce greater levels of cytotoxicity. 
The third task in the study involved micro array analysis of RNA extracted from 
wild type cells at 0 hr, 2 hr, 4 hr or 24 hr post drug treatment to determine the genes 
involved in the observed sensitivity or resistance to each drug. However, the 24 hr time 
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point with the MDA-MB-435 cell line treated with the EC50 concentration of 4DB had to 
be abandoned due to insufficient RNA in these samples. As shown in Figures 18 and 19, 
flow cytometry and fluorescent microscopy studies revealed that the majority of the cells 
in this treatment group were in the active stages of cell death, apoptosis or necrosis, 4 hr 
post treatment with 4DB. Due to the increased level of cell death, the 24 hr time point 
was excluded from these samples and a 2 hr post treatment time point was included in the 
study. 
In order to determine the genes of interest, gene expression levels at each time 
point were compared to the control sample (wild type cells exposed to the drug vehicle 
DMSO). The genes with the highest changes in expression levels, up to five, at each time 
point were identified, resulting in a total of 93 genes with potential involvement in 
response to drug treatment. Of the 93 total genes, 18 genes were identified as common to 
all cell lines upon treatment with each of the three investigated drugs (Tables 6 to 14). 
One common gene to all cell lines with respect to the 4DB treatment was the CHOP 
gene. Over expression of CHOP in response to 4DB treatment could play a role in DNA 
damage signalling which has the potential to induce increased levels of apoptosis. Five of 
the 18 genes common to all cell lines were the heat shock proteins (HSP) HSP72, HSP70, 
HSP60, HSP40 and HSP32. The activity of heat shock proteins involves protecting cells 
from stress by binding and refolding client proteins. HSP72 and HSP70 are members of 
the HSP70 family, which requires the presence of HSP40 to refold client proteins 
(Goloubinoff et al., 2007). HSP60 is considered a mitochondrial chaperonin protein 
which is responsible for transporting and refolding proteins from the cytoplasm into the 
100 
matrix of the mitochondria (Gupta et al, 2002). HSP32 is classified as a small heat shock 
protein and is involved in porphyrin metabolism. This protein has also been characterized 
as a stress related survival protein that has been found in tumours (Sasaki et al, 2005). 
As previously stated, the HSPs identified were found in all cell lines in response to 
each of the drugs. The presence of these proteins in all examined treatment samples 
suggest that although there is protection afforded from each of these drugs, these proteins 
are not responsible for differences in the observed cytotoxicity levels with respect to 4TB 
in the three cell lines. Further analysis of the genes that were over expressed in the 
treatment samples revealed three genes that have the potential to promote the observed 
resistance in the A-549 and DU-145 cell lines to cisplatin and 4TB. Cyclin dependent 
kinase inhibitor (p21), zinc transporter 1 (ZNT1), and metallothionein-lL (MT-1L) were 
over expressed genes in the DU-145 and A-549 cell lines following treatment with 4TB. 
These genes were not over expressed in the MDA-MB-435 treatment samples. The p21 
gene has been shown to be anti apoptotic. The gene is regulated by the tumor suppressor 
protein p53 and is responsible for regulation cell cycle progression through the Gl phase. 
This gene also plays a role in regulating DNA replication and DNA damage repair (Nath, 
2005). The MT-1L gene is responsible for binding heavy metals, such as Zn and Pt, that 
are either physiological or introduced into the cell. MT-1L is believed to provide 
protection against metal toxicity, oxidative stress and supports regulation of zinc and 
copper. MT-1L has the capacity to activate transcription factors through regulation of 
zinc levels (Andrews, 2000; Baraboy et al, 2003). The third gene of interest, ZNT1 is a 
zinc transporter responsible for supporting homeostasis of intracellular zinc levels (Qin et 
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al., 2009). Previous studies have linked cation transport activity with the export of 
platinum containing drugs. Further, increased expression of cation transporters have been 
identified in cell lines that have been characterized as resistant to cisplatin. ZNT1 is of 
particular interest because it has been implicated in activation of MT-1L which in turn 
regulates copper homeostasis by regulation of copper transporters, ATP7A and ATP7B, 
two proteins that have been identified in cisplatin resistant cell types (Kuo et al., 2007). 
The anti apoptotic activity of p21, increased binding of the drug in the cytoplasm by MT-
1L such that the drug does not have the opportunity to form Pt-DNA adducts and export 
of the drug via ZNT1 activities are most likely involved in the observed resistance to 
cisplatin and 4TB in the DU-145 and A-549 wild type cell lines. 
The final task in the current study was to determine if disruption of the DNA 
repair mechanisms, NER and MMR, increased the efficacy of each drug. ERCC1 was the 
target in the disruption of the NER mechanism and MSH2 was the target in the disruption 
of the MSH2 mechanism. Prior to disruption of these proteins, wild type MDA-MB-435, 
DU-145, and A-549 cells were analyzed for each protein using Western blot analysis to 
confirm that these proteins of interest were expressed in each cell line (Figure 20). 
Following confirmation of expression, disruption of each DNA repair mechanism was 
achieved by introducing shRNA inserted in a DNA expression vector (Figure 21) against 
either ERCC1 or MSH2. Four different non-overlapping constructs against each protein 
were transiently transfected into each cell line and the construct that resulted in the 
greatest decrease of protein expression was selected for the creation of a stable cell line. 
As shown in Figures 22, 23 and 24 a construct that sufficiently reduced protein 
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expression was successfully identified by either intracellular antigen staining or Western 
blot analysis. The identified construct as well as positive and negative controls were then 
used to create stable cell lines from each wild type cell line. The nomenclature for each 
developed cell line is given in Table 15. Confirmation of reduced protein expression in 
the cell lines subjected to stable transfection was confirmed was Western blot analysis 
(Figures 25, 26, 27). 
Clonogenic survivals were conducted with the newly developed cell lines to 
determine if disruption of the DNA repair mechanisms would result in a change in 
lethality to each of the three drugs. The newly generated survival curves were used to 
recalculate the EC5o values in each of the developed cell lines for cisplatin, 4TB and 
4DB. As shown in Figure 28 and Table 16, the results of the clonogenic survivals in 
MDA-MB-435 transfected cells revealed that the only statistically significant change in 
the transfected cells compared to wild type or the negative control was in MB-shMSH2 
cell line with respect to cisplatin. The newly calculated EC50 for cisplatin in the MB-
shMSH2 cell line was 975 uM compared to 311 uM in the wild type cell line. An 
increase in the EC50 concentration in a cell line with suppressed MSH2 expression was 
not unexpected. In addition to its role in the MMR mechanism, MSH2 is known to induce 
cell-cycle arrest in the G2 phase upon recognition of mismatched base pairs or damaged 
DNA which allows sufficient time for the cell to repair the DNA prior to entering the S 
phase of the cell cycle. Decreasing levels of MSH2 has the potential to allow continued 
cell cycle progression in cells with genetic instability, resulting in cell survival as well as 
increased levels of mutations. However, MSH2 deficient cell lines have also been tested 
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and results suggest that the effect of MSH2 suppression on drug cytotoxicity warrants 
empirical determination of untested cell lines (Marquez et al., 2003). 
The EC5o values for the A-549 transfected cell lines had similar results to those of 
the MDA-MB-435 transfected cell lines. As shown in Figure 29 and Table 17, the results 
of the clonogenic survivals in A-549 transfected cells revealed that the only statistically 
significant change in the transfected cells compared to wild type or the negative control 
was in A-shMSH2 cell line with respect to cisplatin. The newly calculated EC50 for 
cisplatin in the A-shMSH2 cell line was >1000 uM compared to 850 uM in the wild type 
cell line. 
In the DU-145 cell line (Figure 30 and Table 18), results from the clonogenic 
survivals revealed that the only significant difference in cytotoxicity occurred in the DU-
shERCCl cell line in response to 4TB. The newly calculated EC50 for this cell line with 
4TB was 25.2 JIM as compared to 73.72 uM in the wild type cell line. The data from the 
clonogenic survivals suggests that DNA repair alone does not account for the observed 
resistance or sensitivity to each drug in each cell line. 
Review of all the data generated from each of the tasks lends insight into the 
possible biomarkers and drug characteristics that are responsible for the varying 
cytotoxicity observed between the investigated cell lines. In the MDA-MB-435 cell line, 
the data suggests that increased levels of drug uptake are responsible for the observed 
sensitivity. Changes in levels of gene expression following treatment does not account for 
the observed sensitivity of MDA-MB-435 to each of the drugs. NER silencing also did 
not result in any change in lethality. Interruption of MSH2 with this cell line did result in 
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a significant increase in survival rate upon treatment with 4DB. These data indicate that 
4DB exerts its cytotoxic effects by gaining access to the cell at significantly increased 
levels, 23.25%, and that the MSH2 protein is involved in modulating cellular response to 
this drug. Upon gaining access to the cell, a significant portion of the drug gains access to 
DNA, forms Pt-DNA adducts and is not rapidly repaired over a 24 hr period. MSH2 may 
be responsible for recognizing the DNA damage and committing the cell to apoptosis 
upon recognizing the lesions induced by the presence of 4DB. Given that there are no 
changes in gene expression following drug exposure that would account for increased 
sensitivity (i.e., pro-apoptotic proteins are not over expressed), increased drug uptake 
appears to be the principle cause of lethality. The experiments conducted with the MDA-
MB-435 and the two remaining drugs, 4TB and cisplatin, yield similar results. Sensitivity 
to each drug is correlated to the amount of drug taken up by the cell. Changes in gene 
expression and suppression of DNA repair activity did not change the response of the cell 
line to either of these drugs. 
In the A-549 and DU-145 cell lines, drug uptake also appears to be a central cause 
of cytotoxicity. The cell line's response to each drug is directly correlative to the amount 
of drug taken up by the cell; with increased drug uptake there is increased lethality. 
However, gene expression changes in response to treatment, in both cell lines, also 
appear to play a role in determining sensitivity levels to cisplatin and 4TB. Increased 
levels of MT-1L, p21 and ZNT1 have the potential to bind cisplatin in the cytoplasm, 
prevent the initiation of the apoptotic cascade and actively export the drug from the cell. 
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DNA repair also appears to play a role in the response of these cell lines to these 
drugs. In the A-shMSH2 cell line, there is increased survival upon treatment with 
cisplatin in comparison to the wild type, indicating that normal MSH2 expression levels 
in the cell line, as with MDA-MB-435 cells, may be responsible for recognizing DNA 
damage and committing the cell to apoptosis when the damage is too overwhelming. In 
the DU-shERCCl cell line, there was decreased survival upon treatment with 4TB in 
comparison to the wild type. These data indicate that normal expression of ERCC1 levels 
within the DU-145 cell line actively repairs Pt-DNA adducts formed by 4TB. With 
respect to the 4DB in all cell lines, it appears that the intracellular concentration is so 
elevated that the cell is unable to overcome the cytotoxic effects exerted by increased 
protein binding and Pt-DNA adduct formation. Taken together, these data indicate that 
inhibition of MMR supports increased survival due to reduced cell cycle regulation and 
inhibition of NER decreases Pt-DNA adduct repair resulting in increased levels of cell 
death. 
5.2 Conclusions and Recommendations for Further Study 
The data from the study indicates that drug uptake is positively correlated to drug 
sensitivity. In the cases of drug resistance, overexpression of an apoptotic inhibitor (p21), 
cation transporter (ZNT1) and a protein that binds heavy metals (MT-1L) potentially 
account for resistance. Changes in gene expression levels associated with DNA repair 
following drug treatment were not observed in any of the cell lines, indicating that 
efficiency of DNA repair does not play a critical role in drug resistance. Additionally, 
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levels of HMG proteins were not over expressed in any cell line following drug exposure 
which eliminates this class of proteins as a potential target for modulating drug response. 
Drug uptake levels were identified as critical components of sensitivity or 
resistance to a chemotherapeutic agent. However, the conditions that render the cell 
susceptible or not to drug uptake have not been elucidated. The data from the current 
study suggest a physiological difference inherent in each tissue type with respect to 
cisplatin and 4TB. However, given that 4DB is uniformly taken up by cells at elevated 
concentrations, it is likely that the chemical composition of 4DB is responsible for its 
ability to induce cytotoxicity in the different tissue types, rather than individual 
characteristics of the cells. Understanding the chemical interactions between 4DB and the 
surface of the cell is the most likely approach to allow elucidation of the conditions that 
contribute to the successful entrance and subsequent enhanced cytotoxicity induced by 
this drug. Understanding the interactions between 4DB and the plasma membrane could 
lend valuable insight into the rational drug design of new chemotherapeutic drugs. If 
lower concentrations of the drug are required given their ability to induce increased levels 
of cell death, side effects are likely be less severely toxic and be more tolerable. 
The variations in response to 4TB warrant further study regarding the interactions 
of the drug and the plasma membrane. If the membranes of DU-145 and A-549 cells have 
increased concentrations of molecules that support membrane rigidity and tight junctions 
between cells, these factors could account for decreased levels of drug uptake. For 
example, if there are increased concentrations of cholesterol in the plasma membrane of 
these cells, this could explain the reduced drug uptake and therefore reduced efficacy of 
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4TB. The tertbutyl groups extending from the bipyridine ring system are subject to 
enhanced steric strain in comparison to the n-butyl groups extending from the bipyridine 
ring system in the 4DB drug. The differences in rigidity of these functional groups could 
be responsible for reduction in drug uptake. These factors could not be identified by the 
microarray data from the current study due to the design of the experiment. Microarray 
experiments of exponentially growing wild type cells from each cell line should be 
conducted. The data from each cell line should be used to compare differences between 
tissue types in order to determine if there are expression changes from one cell line to 
another that can account for observed drug uptake levels. 
The microarray data revealed that increased expression of ZNT1 and MT-1L 
correlated to increased survival in the DU-145 and A-549 cells following treatment with 
4TB or cisplatin. Therefore, disruption of these proteins using shRNA and assessing 
changes in cytotoxicity using clonogenic survivals should be conducted to determine if 
these proteins are involved in drug response. Disruption of one or both targets with 
concurrent improvement in cytotoxicity could indicate that these proteins support 
survival following drug treatment. 
Additional studies using these drugs within normal tissue types also warrants 
investigation. The success of 4DB at inducing high levels of cell kill is a promising 
results. Therefore, clonogenic survivals should be conducted to empirically determine the 
cytotoxic effects of 4DB in tissues that have been identified as particularly susceptible to 
platinum compounds such as kidney epithelial cells. 
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In conclusion, it appears that drug sensitivity is only minimally impacted by the 
disrpution of DNA repair mechanisms in the MDA-MB-435, A-549 and DU-145 cells. 
Increased drug uptake positively correlates to cytotoxicity. In the A-549 and DU-145 
cells, the upregulation of p21, MT-1L and ZNT1 are potential contributors to the 
observed resistance in these cell lines to 4TB and cisplatin. Determining the specific 
interactions that allow for increased drug uptake will support future efforts in designing 
new chemotherapeutics which have increased efficacy with less severe side effects in 
comparison to currently used chemotherapeutics. 
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